What changed in this filing

/stocks — the workspaceLOADING

Item 1A. Risk Factors

2022-03-29 compared with 2021-03-30 · 1626 added, 1519 removed, 79 unchanged (98% of the section changed)

Summary Risk Factors

The following is a summary of material risks that could affect

our business.

This summary may not contain all of our material risks, and it is qualified in its entirety by the more detailed

risk factors set forth below.

The following is a summary of material risks that could affect our

This summary may not contain all of our material risks, and it is qualified in its entirety by the more detailed risk factors

set forth below.

Risks Related to our Financial Position and Need for Additional

We have a history of operating losses, expect to incur

additional operating losses in the future and may never be profitable.

Our cost of operations could increase significantly more than what we expect depending on the costs to complete our development

program for DefenCath/Neutrolin.

We will need to finance our future cash needs through public or private equity offerings, debt financings or corporate collaboration

and licensing arrangements.

Any additional funds that we obtain may not be on terms favorable to us or our stockholders and may

require us to relinquish valuable rights.

Risks Related to the Development and Commercialization

of Our Product Candidates

Defencath, our lead product candidate, has received Fast Track designation and Qualified Infectious Disease Product designation

from FDA, but we cannot provide assurances that these designations will not be rescinded.

If the FDA requires a second clinical trial for DefenCath or imposes additional manufacturing requirements

to approve the New Drug Application, the development of DefenCath will take longer and cost more to complete, and we will need

significant additional funds to undertake a second trial, if required.

Our only product Neutrolin is only approved in Europe and is still in development in the United States.

Final approval by regulatory authorities of our product candidates for commercial use may be delayed, limited or prevented,

any of which would adversely affect our ability to generate operating revenues.

Successful development and commercialization of our other products is uncertain.

If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties

or incur costs that could harm our business.

The successful commercialization of Neutrolin will depend on obtaining coverage and reimbursement for use of Neutrolin from

third-party payors.

We have a history of operating losses, expect to incur additional

operating losses in the future and may never be profitable.

Our cost of operations could increase significantly more than what

we expect depending on the costs to complete our development program for DefenCath/Neutrolin.

We will need to finance our future cash needs through public or private

equity offerings, debt financings or corporate collaboration and licensing arrangements.

Any additional funds that we obtain may not be on terms favorable to us or our stockholders

and may require us to relinquish valuable rights.

Risks Related to the Development and Commercialization of Our

Product Candidates

Defencath, our lead product candidate, has received Fast Track designation

and Qualified Infectious Disease Product designation from FDA, but we cannot provide assurances

that these designations will not be rescinded.

If the FDA requires a second clinical

trial for DefenCath or imposes additional manufacturing requirements to approve the New Drug

Application, the development of DefenCath will take longer and cost more to complete, and

we will need significant additional funds to undertake a second trial, if required.

Our only product Neutrolin is only approved in Europe and is still

in development in the United States.

Final approval by regulatory authorities of our product candidates

for commercial use may be delayed, limited or prevented, any of which would adversely affect

our ability to generate operating revenues.

Successful development and commercialization of our other products

is uncertain.

If we fail to comply with environmental, health and safety laws and

regulations, we could become subject to fines or penalties or incur costs that could harm

our business.

The successful commercialization of Neutrolin will depend on obtaining

coverage and reimbursement for use of Neutrolin from third-party payors.

Physician and patients may not accept and use our products.

Changes in funding for the FDA and other government agencies or future government shutdowns or disruptions could cause delays

in the submission and regulatory review of marketing applications, which could negatively impact our business or prospects.

The outbreak of the novel coronavirus disease, COVID-19, or other pandemic, epidemic or outbreak of an infectious disease may

materially and adversely impact our business, including our preclinical studies and clinical trials.

Clinical trials required for our product candidates may be expensive and time-consuming, and their outcome is uncertain.

If we fail to comply with international regulatory requirements, we could be subject to regulatory delays, fines or other penalties.

We do not have, and may never obtain, the regulatory approvals we need to market our product candidates outside of the European

Even if approved, our products will be subject to extensive post-approval regulation.

Changes in funding for the FDA and other government agencies or future

government shutdowns or disruptions could cause delays in the submission and regulatory review

of marketing applications, which could negatively impact our business or prospects.

The ongoing COVID-19 pandemic, or other pandemic, epidemic or outbreak

of an infectious disease may materially and adversely impact our business, including our preclinical studies and clinical trials.

Clinical trials required for our product candidates may be expensive

and time-consuming, and their outcome is uncertain.

If we fail to comply with international regulatory requirements,

we could be subject to regulatory delays, fines or other penalties.

We do not have, and may never obtain, the regulatory approvals we

need to market our product candidates outside of the European Union.

Even if approved, our products will be subject to extensive post-approval

Risks Related to Our Business and Industry

Competition and technological change may make our product candidates and technologies less attractive or obsolete.

Healthcare policy changes, including reimbursement policies for drugs and medical devices, may have an adverse effect on our

business, financial condition and results of operations.

If we lose key management or scientific personnel, cannot recruit qualified employees, directors, officers, or other personnel

or experience increases in compensation costs, our business may materially suffer.

If we are unable to hire additional qualified personnel, our ability to grow our business may be harmed.

Competition and technological change may make our product candidates

and technologies less attractive or obsolete.

Healthcare policy changes, including reimbursement policies for drugs

and medical devices, may have an adverse effect on our business, financial condition and

results of operations.

If we lose key management or scientific personnel, cannot recruit

qualified employees, directors, officers, or other personnel or experience increases in compensation

costs, our business may materially suffer.

If we are unable to hire additional qualified personnel, our ability

to grow our business may be harmed.

We may not successfully manage our growth.

We face the risk of product liability claims and the amount of insurance coverage we hold now or in the future may not be adequate

to cover all liabilities we might incur.

We may be exposed to liability claims associated with the use of hazardous materials and chemicals.

We face the risk of product liability claims and the amount of insurance

coverage we hold now or in the future may not be adequate to cover all liabilities we might

We may be exposed to liability claims associated with the use of

hazardous materials and chemicals.

Negative U.S.

and global economic conditions may pose challenges to our business strategy, which relies on funding from the

financial markets or collaborators.

and global economic conditions may pose challenges

to our business strategy, which relies on funding from the financial markets or collaborators.

Risks Related to Our Intellectual Property

If we materially breach or default under any of our license agreements, the licensor party to such agreement will have the

right to terminate the license agreement, which termination may materially harm our business.

If we and our licensors do not obtain protection for and successfully defend our respective intellectual property rights, competitors

may be able to take advantage of our research and development efforts to develop competing products.

Ongoing and future intellectual property disputes could require us to spend time and money to address such disputes and could

limit our intellectual property rights.

The decisions by the European and German patent offices may affect patent rights in other jurisdictions.

If we infringe the rights of third parties we could be prevented from selling products and forced to pay damages and defend

against litigation.

If we materially breach or default under any of our license agreements,

the licensor party to such agreement will have the right to terminate the license agreement,

which termination may materially harm our business.

If we and our licensors do not obtain protection for and successfully

defend our respective intellectual property rights, competitors may be able to take advantage

of our research and development efforts to develop competing products.

Ongoing and future intellectual property disputes could require us

to spend time and money to address such disputes and could limit our intellectual property

The decisions by the European and German patent offices may affect

patent rights in other jurisdictions.

If we infringe the rights of third parties we could be prevented

from selling products and forced to pay damages and defend against litigation.

Risks Related to Dependence on Third Parties

We currently have no internal marketing and sales organization and currently rely and intend to continue to rely on third parties

to market, sell, and distribute Neutrolin outside of the U.S.

We currently have no internal marketing and sales organization and

currently rely and intend to continue to rely on third parties to market, sell, and distribute

Neutrolin outside of the U.S.

We may seek a sales partner in the U.S.

if DefenCath receives FDA

approval or we may undertake marketing and sales of DefenCath in the U.S.

If we are unable to enter into or maintain

agreements with third parties to market and sell DefenCath or any other product after approval or are unable to find a sales partner

or establish our own marketing and sales capabilities, we may not be able to generate significant or any product revenues.

If we or our collaborators are unable to manufacture our products in sufficient quantities or are

unable to obtain regulatory approvals for a manufacturing facility, we may be unable to meet demand for our products and we may

if DefenCath receives

FDA approval or we may undertake marketing and sales of DefenCath in the U.S.

If we are unable to enter into or maintain agreements with third parties to market and sell

DefenCath or any other product after approval or are unable to find a sales partner or establish

our own marketing and sales capabilities, we may not be able to generate significant or any

product revenues.

If we or our collaborators are unable

to manufacture our products in sufficient quantities or are unable to obtain regulatory approvals

for a manufacturing facility, we may be unable to meet demand for our products and we may

lose potential revenues.

Corporate and academic collaborators may take actions that delay, prevent, or undermine the success of our products.

Data provided by collaborators and others upon which we rely that has not been independently verified could turn out to be

false, misleading, or incomplete.

We rely on third parties to conduct our clinical trials and pre-clinical studies.

If those parties do not successfully carry

out their contractual duties or meet expected deadlines, our product candidates may not advance in a timely manner or at all.

We will depend on third party suppliers and contract manufacturers for the manufacturing of our product candidates and have

no direct control over the cost of manufacturing our product candidates.

Increases in the cost of manufacturing our product candidates

would increase our costs of conducting clinical trials and could adversely affect our future profitability.

Corporate and academic collaborators may take actions that delay,

prevent, or undermine the success of our products.

Data provided by collaborators and others upon which we rely that

has not been independently verified could turn out to be false, misleading, or incomplete.

We rely on third parties to conduct our clinical trials and pre-clinical

If those parties do not successfully carry out their contractual duties or meet

expected deadlines, our product candidates may not advance in a timely manner or at all.

We will depend on third party suppliers and contract manufacturers

for the manufacturing of our product candidates and have no direct control over the cost

of manufacturing our product candidates.

Increases in the cost of manufacturing our product

candidates would increase our costs of conducting clinical trials and could adversely affect

our future profitability.

Risks Related to Our Common Stock

We will need additional financing to fund our activities in the future, which likely will dilute our stockholders.

Our executive officers and directors may sell shares of their stock, and these sales could adversely affect our stock price.

Our common stock price has fluctuated considerably and is likely to remain volatile, in part due to the limited market for

our common stock and you could lose all or a part of your investment.

A significant number of additional shares of our common stock may be issued at a later date, and their sale could depress the

market price of our common stock.

Provisions in our corporate charter documents and under Delaware law could make an acquisition of us, which may be beneficial

to our stockholders, more difficult.

If we fail to comply with the continued listing standards of the Nasdaq Global Market, it may result in a delisting of our

common stock from the exchange.

Laws, rules and regulations relating to public companies may be costly and impact our ability to attract and retain directors

and executive officers.

Our internal control over financial reporting and our disclosure controls and procedures may not prevent all possible errors

that could occur.

Security breaches and other disruptions could compromise our information and expose us to liability, which would cause our

business and reputation to suffer.

We do not intend to pay dividends on our common stock so any returns on our common stock will be limited to the value of our

common stock.

Related to Our Financial Position and Need for Additional Capital

have a history of operating losses, expect to incur additional operating losses in the future and may never be profitable.

prospects must be considered in light of the uncertainties, risks, expenses, and difficulties frequently encountered by companies

in the early stages of operation.

We incurred net losses of approximately $22.0 million and $16.4 million for the years ended

December 31, 2020 and 2019, respectively.

As of December 31, 2020, we had an accumulated deficit of approximately $217.4 million.

We expect to incur substantial additional operating expenses over the next several years as our research, development, pre-clinical

testing, clinical trial and commercialization activities increase as we develop and commercialize DefenCath and our other product

As a result, we expect to experience negative cash flow as we fund our operating losses and capital expenditures.

We will need additional financing to fund our activities in the future,

which likely will dilute our stockholders.

Our executive officers and directors may sell shares of their stock,

and these sales could adversely affect our stock price.

Our common stock price has fluctuated considerably and is likely

to remain volatile, in part due to the limited market for our common stock and you could

lose all or a part of your investment.

A significant number of additional shares of our common stock may

be issued at a later date, and their sale could depress the market price of our common stock.

Provisions in our corporate charter documents and under Delaware

law could make an acquisition of us, which may be beneficial to our stockholders, more difficult.

If we fail to comply with the continued listing standards of the

Nasdaq Global Market, it may result in a delisting of our common stock from the exchange.

Laws, rules and regulations relating to public companies may be costly

and impact our ability to attract and retain directors and executive officers.

Our internal control over financial reporting and our disclosure

controls and procedures may not prevent all possible errors that could occur.

Security breaches and other disruptions could compromise our information

and expose us to liability, which would cause our business and reputation to suffer.

We do not intend to pay dividends on our common stock so any returns

on our common stock will be limited to the value of our common stock.

Risks Related to Our Financial Position

and Need for Additional Capital

We have a history of operating losses, expect to incur additional

operating losses in the future and may never be profitable.

Our prospects must be considered in light of the

uncertainties, risks, expenses, and difficulties frequently encountered by companies in the early stages of operation.

We incurred net

losses of approximately $28.2 million and $22.0 million for the years ended December 31, 2021 and 2020, respectively.

As of December 31,

2021, we had an accumulated deficit of approximately $245.7 million.

We expect to incur substantial additional operating expenses over

the next several years as our research, development, pre-clinical testing, clinical trial and commercialization activities increase as

we develop and commercialize DefenCath and our other product candidates.

As a result, we expect to experience negative cash flow as we

fund our operating losses and capital expenditures.

The amount of future losses and when, if ever, we will achieve profitability are uncertain.

Neutrolin was launched in December

2013 and is currently available for distribution in certain European Union and Middle East countries.

We have not generated any

significant commercial revenue and do not expect to generate substantial revenues from DefenCath unless and until it is approved

by the United States Food and Drug Administration (“FDA”) and launched in the United States (“U.S.”) market,

and we might never generate significant revenues from the sale of DefenCath or any other products.

Our ability to generate revenue

and achieve profitability will depend on, among other things, the following:

obtaining FDA approval of DefenCath for the prevention

of catheter-related bloodstream infections (“CRBSIs”) in patients with kidney failure receiving hemodialysis through

a central venous catheter;

Neutrolin was launched in December 2013 and is currently available for distribution in certain European Union countries.

We have not generated

any significant commercial revenue and do not expect to generate substantial revenues from DefenCath unless and until it is approved by

the United States Food and Drug Administration (“FDA”) and launched in the United States (“U.S.”) market, and

we might never generate significant revenues from the sale of DefenCath or any other products.

Our ability to generate revenue and achieve

profitability will depend on, among other things, the following:

obtaining FDA approval of DefenCath for the prevention of catheter-related

bloodstream infections (“CRBSIs”) in patients with kidney failure receiving hemodialysis through a central venous catheter;

successfully launching and marketing DefenCath in the U.S., if approved by the FDA;

successfully marketing

Neutrolin in foreign countries in which it is approved for sale;

obtaining necessary regulatory approvals for our other product

candidates from the FDA and, if sought, international regulatory agencies;

establishing manufacturing, sales, and marketing arrangements,

either alone or with third parties;

successfully marketing Neutrolin in foreign countries

in which it is approved for sale;

obtaining necessary regulatory approvals for our other product candidates from the FDA and, if sought,

international regulatory agencies;

establishing manufacturing, sales, and marketing arrangements, either alone or with third parties;

and raising sufficient funds to finance our activities.

We might not succeed at any of these

undertakings.

If we are unsuccessful at some or all of these undertakings, our business, prospects, and results of operations

may be materially adversely affected.

cost of operations could increase significantly more than what we expect depending on the costs to complete our development program

for DefenCath.

operations are subject to a number of factors that can affect our operating results and financial condition.

Such factors include,

but are not limited to:

the results of clinical testing and trial activities of our product candidates;

the ability to obtain

regulatory approval to market our products;

We might not succeed at any of these undertakings.

If we are unsuccessful at some

or all of these undertakings, our business, prospects, and results of operations may be materially adversely affected.

Our cost of operations could increase significantly more than

what we expect depending on the costs to complete our development program for DefenCath.

Our operations are subject to

a number of factors that can affect our operating results and financial condition.

Such factors include, but are not limited to:

results of clinical testing and trial activities of our product candidates;

the ability to obtain regulatory approval to market our products;

ability to manufacture successfully;

competition from products manufactured and sold

or being developed by other companies;

the price of, and demand for, our products;

our ability to negotiate favorable licensing

or other manufacturing and marketing agreements for our products;

competition from products manufactured and sold or being developed by other companies;

of, and demand for, our products;

our ability to negotiate favorable licensing or other manufacturing and marketing agreements for our

and our ability to raise capital to support our operations.

To date, our commercial operations have not generated sufficient

revenues to enable profitability.

As of December 31, 2020, we had an accumulated deficit of $217.4 million, and incurred net losses

of $22.0 million for the year then ended.

To date, our commercial operations have not generated

sufficient revenues to enable profitability.

As of December 31, 2021, we had an accumulated deficit of $245.7 million, and incurred net

losses of $28.2 million for the year then ended.

Based on the current development plans for DefenCath and Neutrolin in both the U.S.

foreign markets (including the concluded hemodialysis Phase 3 clinical trial in the U.S.) and our other operating requirements,

management believes that the existing cash at December 31, 2020, after taking into consideration the $41.5 million of net proceeds

received in January and February 2021 from the at-the-market program, will be sufficient to fund operations at least into the second

half of 2022.

We will need additional funding for the commercialization of DefenCath upon FDA approval and funding for the label

expansion studies for DefenCath into oncology and total parenteral nutrition.

continued operations will ultimately depend on our ability to raise additional capital through various potential sources, such

as equity and/or debt financings, strategic relationships, potential strategic transactions or out-licensing of our products in

order to complete the development of DefenCath and until we achieve profitability, if ever.

We can provide no assurances that

such financing or strategic relationships will be available on acceptable terms, or at all.

Without this funding, we could be

required to delay, scale back or eliminate some or all of our research and development programs which would likely have a material

adverse effect on our business.

will need to finance our future cash needs through public or private equity offerings, debt financings or corporate collaboration

and licensing arrangements.

Any additional funds that we obtain may not be on terms favorable to us or our stockholders and may

require us to relinquish valuable rights.

have launched Neutrolin in certain European Union and Middle East countries, but to date have no other approved product on the

market and have not generated significant product revenue from Neutrolin to date.

Unless and until we receive applicable regulatory

approval for DefenCath in the U.S., we cannot sell DefenCath in the U.S.

Therefore, for the foreseeable future, we will have to

fund all of our operations and capital expenditures from Neutrolin sales in Europe and other foreign markets, if approved, cash

on hand, additional financings, licensing fees and grants.

foreign markets (including the concluded hemodialysis Phase 3 clinical trial in the U.S.) and our other operating requirements, management

believes that the existing cash at December 31, 2021, after taking into consideration the costs for resubmission of the NDA and initial

preparations for the commercial launch for DefenCath, will be sufficient to fund operations at least through the first half of 2023.

will need additional funding for the commercialization of DefenCath upon FDA approval and funding for the label expansion studies for

Our continued operations will ultimately depend

on our ability to raise additional capital through various potential sources, such as equity and/or debt financings, strategic relationships,

potential strategic transactions or out-licensing of our products in order to complete the development of DefenCath and until we achieve

profitability, if ever.

We can provide no assurances that such financing or strategic relationships will be available on acceptable terms,

Without this funding, we could be required to delay, scale back or eliminate some or all of our research and development programs

which would likely have a material adverse effect on our business.

We will need to finance our future cash needs through public

or private equity offerings, debt financings or corporate collaboration and licensing arrangements.

Any additional funds that we obtain

may not be on terms favorable to us or our stockholders and may require us to relinquish valuable rights.

have launched Neutrolin in certain European Union and Middle East countries, but to date have no other approved product on the market

and have not generated significant product revenue from Neutrolin to date.

Unless and until we receive applicable regulatory approval

for DefenCath in the U.S., we cannot sell DefenCath in the U.S.

Therefore, for the foreseeable future, we will have to fund all of our

operations and capital expenditures from Neutrolin sales in Europe and other foreign markets, if approved, cash on hand, additional financings,

licensing fees and grants.

We believe that our cash resources as of December

after taking into consideration the $41.5 million of net proceeds received in January and February 2021 from the at-the-market

program, will be sufficient to fund operations at least into the second half of 2022.

31, 2021, after taking into consideration the costs for resubmission of the NDA and initial preparations for the commercial launch for

DefenCath, will be sufficient to fund operations at least through the first half of 2023.

Nevertheless, we may need to raise additional

funds through financings or strategic relationships if our costs exceed our expectations, as well as funds for our operations beyond

the second half of 2022.

We can provide no assurances that any financing or strategic relationships will be available to us on

acceptable terms, or at all.

We expect to continue to use significant cash to fund our operations as we seek FDA approval of DefenCath

in the U.S., commercialize Neutrolin in Europe and other markets, pursue development of our medical devices and other business

development activities, and incur additional legal costs to defend our intellectual property.

raise needed capital, we may sell additional equity or debt securities, obtain a bank credit facility, or enter into a corporate

collaboration or licensing arrangement.

The sale of additional equity or debt securities, if convertible, could result in dilution

to our stockholders.

The incurrence of indebtedness would result in fixed obligations and could also result in covenants that

would restrict our operations.

Raising additional funds through collaboration or licensing arrangements with third parties may

require us to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates,

or to grant licenses on terms that may not be favorable to us or our stockholders.

Related to the Development and Commercialization of Our Product Candidates

our lead product candidate, has received Fast Track designation and Qualified Infectious Disease Product designation from FDA,

but we cannot provide assurances that these designations will not be rescinded.

is being developed as a catheter lock solution for the reduction of CRBSIs in patients with kidney failure receiving hemodialysis

through a central venous catheter.

The FDA has determined that DefenCath will be regulated as a New Drug, because it contains

the new chemical entity taurolidine as a novel antimicrobial agent.

After we filed the Investigational New Drug Application (“IND”),

FDA granted designations as Fast Track and a Qualified Infectious Disease Product (“QIDP”) in January 2015.

is designed to facilitate development of a drug that is intended to treat a serious or life-threatening condition and address

an unmet medical need.

Fast Track confers eligibility to request priority review of an NDA, with FDA’s decision regarding

potential priority review to be made after receipt of a complete application.

QIDP was established pursuant to the Generating

Antibiotic Incentives Now (“GAIN”) Act and creates incentives for the development of antibacterial and antifungal

drug products that treat serious or life-threatening infections.

Subject to the specified statutory limitations, a drug that is

designated as QIDP and is approved for the use for which the QIDP designation was granted will receive a 5-year extension to any

exclusivity for which the application qualifies upon approval, such as the 5 year exclusivity for a new chemical entity.

funds through financings or strategic relationships if our costs exceed our expectations, as well as funds for our continued operations.

We can provide no assurances that any financing or strategic relationships will be available to us on acceptable terms, or at all.

expect to continue to use significant cash to fund our operations as we seek FDA approval of DefenCath in the U.S., commercialize Neutrolin

in Europe and other markets, pursue development of our medical devices and other business development activities, and incur additional

legal costs to defend our intellectual property.

To raise needed capital, we may sell

additional equity or debt securities, obtain a bank credit facility, or enter into a corporate collaboration or licensing arrangement.

The sale of additional equity or debt securities, if convertible, could result in dilution to our stockholders.

The incurrence of indebtedness

would result in fixed obligations and could also result in covenants that would restrict our operations.

Raising additional funds through

collaboration or licensing arrangements with third parties may require us to relinquish valuable rights to our technologies, future revenue

streams, research programs or product candidates, or to grant licenses on terms that may not be favorable to us or our stockholders.

Risks Related to the Development and Commercialization

of Our Product Candidates

DefenCath, our lead product candidate, has received Fast Track

designation and Qualified Infectious Disease Product designation from FDA, but we cannot provide assurances that these designations will

not be rescinded.

DefenCath is being developed as a catheter lock

solution for the reduction of CRBSIs in patients with kidney failure receiving hemodialysis through a central venous catheter.

has determined that DefenCath will be regulated as a New Drug, because it contains the new chemical entity taurolidine as a novel antimicrobial

After we filed the Investigational New Drug Application (“IND”), FDA granted designations as Fast Track and a Qualified

Infectious Disease Product (“QIDP”) in January 2015.

Fast Track is designed to facilitate development of a drug that is intended

to treat a serious or life-threatening condition and address an unmet medical need.

Fast Track confers eligibility to request priority

review of an NDA, with FDA’s decision regarding potential priority review to be made after receipt of a complete application.

was established pursuant to the Generating Antibiotic Incentives Now (“GAIN”) Act and creates incentives for the development

of antibacterial and antifungal drug products that treat serious or life-threatening infections.

Subject to the specified statutory limitations,

a drug that is designated as QIDP and is approved for the use for which the QIDP designation was granted will receive a 5-year extension

to any exclusivity for which the application qualifies upon approval, such as the 5 year exclusivity for a new chemical entity.

provide assurances that DefenCath will retain these designations and continue to receive the benefits conferred.

the FDA requires a second clinical trial for DefenCath or imposes additional manufacturing requirements to approve the New Drug

Application, the development of DefenCath will take longer and cost more to complete, and we will need significant additional

funds to undertake a second trial, if required.

Although two pivotal

clinical trials to demonstrate safety and effectiveness of DefenCath are generally required by the FDA to secure marketing approval

in the U.S., FDA will in some cases accept one adequate and well-controlled trial, where it is a large multicenter trial with a

broad range of subjects and investigation sites with procedures to include trial quality that has demonstrated a clinically meaningful

and statistically very persuasive effect on prevention of a disease with potentially serious outcome.

We discussed submission of

the NDA with the FDA based on the data from LOCK-IT-100 and were granted our request for rolling submission and review of the NDA

for DefenCath as a catheter lock solution for the prevention of CRBSIs in patients with end stage renal disease receiving hemodialysis

through a central venous catheter.

In August 2020, the FDA accepted the DefenCath NDA for filing and granted our request for priority

review, with a PDUFA date of February 28, 2021.

As we announced in March 2021, the FDA informed us in a Complete Response Letter

that it will not approve the NDA in its present form, because of concerns at the third-party manufacturing facility and a requirement

to conduct a manual extraction study to demonstrate that the labeled volume can be consistently withdrawn from the vials.

to meet with the FDA to obtain agreement on the proposed resolutions of the deficiencies.

The FDA did not request additional clinical

data and did not identify any deficiencies related to the data submitted on the efficacy and safety of DefenCath from LOCK-IT-100.

In draft labeling discussed with FDA, the FDA added that the initial approval will be for the limited population of patients with

kidney failure receiving hemodialysis through a central venous catheter.

This is consistent with our request for approval of the

NDA pursuant to the Limited Population Pathway for Antibacterial and Antifungal Drugs (“LPAD”) pathway, which was passed

as part of the 21st Century Cures Act.

LPAD is intended to expedite the development and approval of certain antibacterial and antifungal

drugs which meet three criteria:

intended to treat serious or life-threatening infections;

If the FDA requires a second clinical trial for DefenCath or

imposes additional manufacturing requirements to approve the New Drug Application, the development of DefenCath will take longer and

cost more to complete, and we will need significant additional funds to undertake a second trial, if required.

Although two pivotal clinical trials to demonstrate

safety and effectiveness of DefenCath are generally required by the FDA to secure marketing approval in the U.S., FDA will in some cases

accept one adequate and well-controlled trial, where it is a large multicenter trial with a broad range of subjects and investigation

sites with procedures to include trial quality that has demonstrated a clinically meaningful and statistically very persuasive effect

on prevention of a disease with potentially serious outcome.

We discussed submission of the NDA with the FDA based on the data from LOCK-IT-100

and were granted our request for rolling submission and review of the NDA for DefenCath as a catheter lock solution for the prevention

of CRBSIs in patients with end stage renal disease receiving hemodialysis through a central venous catheter.

In August 2020, the FDA

accepted the DefenCath NDA for filing and granted our request for priority review, with a PDUFA date of February 28, 2021.

As we announced

in March 2021, the FDA informed us in a Complete Response Letter that it will not approve the NDA in its present form, because of concerns

at the third-party manufacturing facility and a requirement to conduct a manual extraction study to demonstrate that the labeled volume

can be consistently withdrawn from the vials.

The FDA did not request additional clinical data and did not identify any deficiencies

related to the data submitted on the efficacy and safety of DefenCath from LOCK-IT-100.

In draft labeling discussed with FDA, the FDA

added that the initial approval will be for the limited population of patients with kidney failure receiving hemodialysis through a central

venous catheter.

This is consistent with our request for approval of the NDA pursuant to the Limited Population Pathway for Antibacterial

and Antifungal Drugs (“LPAD”) pathway, which was passed as part of the 21st Century Cures Act.

LPAD is intended to expedite

the development and approval of certain antibacterial and antifungal drugs which meet three criteria:

intended to treat serious

or life-threatening infections;

in limited populations of patients;

and with unmet needs.

The LPAD pathway provides for a streamlined clinical development program for a limited population that may

involve smaller, shorter or fewer clinical trials.

Labeling of an LPAD approved product will specify the use in the limited population.

However, until the NDA is approved, if we experience issues related to the clinical trial results, we may incur additional costs

and delays in the trial, and may not be able to complete the clinical trial in a cost-effective or timely manner, which would have

an adverse effect on our development program for DefenCath as a treatment for catheter-related bloodstream infections.

only product Neutrolin is only approved in Europe and is still in development in the United States.

currently and for at least the near future is our only current product as well as product candidate.

Neutrolin has received CE

Mark approval in Europe, and we started sales in Germany in December 2013.

We also are pursuing development of DefenCath in the

Our product commercialization and development efforts may not lead to commercially viable products for any of several reasons.

For example, our product candidates may fail to be proven safe and effective in clinical trials, or we may have inadequate financial

or other resources to pursue development efforts for our product candidates.

Even if approved, our product may not be accepted

in the marketplace.

DefenCath will require significant additional development, including the preparation and filing of an NDA,

possibly a second clinical trial, and/or investment by us or our collaborators as we continue its commercialization, as will any

other product candidates.

In April 2017, we entered

into a commercial collaboration with Hemotech SAS covering France and certain overseas territories.

We have an agreement with a

South Korean company to market, sell and distribute Neutrolin in South Korea upon receipt of regulatory approval in that country,

which requires approval by the U.S.

We also have commercial sales in Germany and a distributor agreement for the United Arab

Emirates, which is pursuant to the EU CE Mark.

Consequently, we will be dependent on these companies and individuals for the success

of sales in those countries and any other countries in which we receive regulatory approval and in which we contract with third

parties for the marketing, sale and/or distribution of Neutrolin.

If these companies or individuals do not perform for whatever

reason, our business, prospects and results of operations will be adversely affected.

Finding a suitable replacement organization

or individual for these or any other companies or individuals with whom we might contract could be difficult, which would further

harm our business, prospects and results of operations.

The negotiation and consummation of collaboration agreements typically

involve simultaneous discussions with multiple potential collaborators and require significant time and resources.

in attracting the attention of pharmaceutical and biotechnology company collaborators, we compete with numerous other third parties

with product opportunities as well as the collaborators’ own internal product opportunities.

We may not be able to consummate

collaborative agreements, or we may not be able to negotiate commercially acceptable terms for these agreements.

The LPAD pathway provides for a streamlined

clinical development program for a limited population that may involve smaller, shorter or fewer clinical trials.

Labeling of an LPAD

approved product will specify the use in the limited population.

We have resubmitted the NDA after addressing the manufacturing issues,

but until the NDA is approved, if FDA raises issues related to the clinical trial results, we may incur additional costs and delays in

the trial, and may not be able to complete the clinical trial in a cost-effective or timely manner, which would have an adverse effect

on our development program for DefenCath as a treatment for catheter-related bloodstream infections.

Our only product Neutrolin is only approved in Europe and is

still in development in the United States.

Neutrolin currently and for at least the near future

is our only current product as well as product candidate.

Neutrolin has received CE Mark approval in Europe, and we started sales in Germany

in December 2013.

We also are pursuing development of DefenCath in the U.S.

Our product commercialization and development efforts may

not lead to commercially viable products for any of several reasons.

For example, our product candidates may fail to be proven safe and

effective in clinical trials, or we may have inadequate financial or other resources to pursue development efforts for our product candidates.

Even if approved, our product may not be accepted in the marketplace.

DefenCath will require approval by the FDA of an NDA and/or investment

by us or our collaborators as we continue its commercialization, as will any other product candidates.

In April 2017, we entered into a commercial collaboration

with Hemotech SAS covering France and certain overseas territories.

We have an agreement with a South Korean company to market, sell

and distribute Neutrolin in South Korea upon receipt of regulatory approval in that country, which requires approval by the U.S.

We also have commercial sales in Germany and a distributor agreement for the United Arab Emirates, which is pursuant to the EU CE Mark.

Consequently, we will be dependent on these companies and individuals for the success of sales in those countries and any other countries

in which we receive regulatory approval and in which we contract with third parties for the marketing, sale and/or distribution of Neutrolin.

If these companies or individuals do not perform for whatever reason, our business, prospects and results of operations will be adversely

Finding a suitable replacement organization or individual for these or any other companies or individuals with whom we might

contract could be difficult, which would further harm our business, prospects and results of operations.

The negotiation and consummation

of collaboration agreements typically involve simultaneous discussions with multiple potential collaborators and require significant

time and resources.

In addition, in attracting the attention of pharmaceutical and biotechnology company collaborators, we compete with

numerous other third parties with product opportunities as well as the collaborators’ own internal product opportunities.

not be able to consummate collaborative agreements, or we may not be able to negotiate commercially acceptable terms for these agreements.

Final approval by regulatory authorities

of our product candidates for commercial use may be delayed, limited or prevented, any of which would adversely affect our ability

to generate operating revenues.

Our ability to generate

operating revenue will be severely limited until we, a licensee, or a potential collaborator successfully commercializes DefenCath

in the United States.

We may experience unforeseen events during product development that may substantially delay or prevent product

For example, in the course of conducting a clinical trial, the FDA could order the temporary, or permanent, discontinuation

at any time if it believes that the clinical trial either is not being conducted in accordance with FDA requirements or presents

an unacceptable risk to the clinical trial patients.

An Institutional Review Board (“IRB”) may also require the clinical

trial at the site to be halted, either temporarily or permanently, for failure to comply with the IRB’s requirements or if

the trial poses an unexpected serious harm to clinical trial patients.

The FDA or an IRB may also impose conditions on the conduct

of a clinical trial.

Clinical trial sponsors may also choose to discontinue clinical trials as a result of risks to clinical trial

patients, a lack of favorable results, or changing business priorities.

of our product candidates for commercial use may be delayed, limited or prevented, any of which would adversely affect our ability to

generate operating revenues.

Our ability to generate operating

revenue will be severely limited until we, a licensee, or a potential collaborator successfully commercializes DefenCath in the United

We may experience unforeseen events during product development that may substantially delay or prevent product approval.

example, in the course of conducting a clinical trial, the FDA could order the temporary, or permanent, discontinuation at any time if

it believes that the clinical trial either is not being conducted in accordance with FDA requirements or presents an unacceptable risk

to the clinical trial patients.

An Institutional Review Board (“IRB”) may also require the clinical trial at the site to

be halted, either temporarily or permanently, for failure to comply with the IRB’s requirements or if the trial poses an unexpected

serious harm to clinical trial patients.

The FDA or an IRB may also impose conditions on the conduct of a clinical trial.

Clinical trial

sponsors may also choose to discontinue clinical trials as a result of risks to clinical trial patients, a lack of favorable results,

or changing business priorities.

The clinical development,

1 unchanged sentence

relating to our product candidates are subject to extensive regulation by the FDA and other regulatory agencies.

Failure to comply

with applicable regulatory requirements may, either before or after product approval, subject us to administrative or judicially

imposed sanctions that may negatively impact the approval of one or more of our product candidates or otherwise negatively impact

our business.

Compliance with such regulations may consume substantial financial and management resources and expose us and our

collaborators to the potential for other adverse circumstances.

For example, a regulatory authority can place restrictions on the

sale or marketing of a drug in order to manage the risks identified during initial clinical trials or after the drug is on the

A regulatory authority can condition the approval for a drug on costly post-marketing follow-up studies.

Based on these

studies, if a regulatory authority does not believe that the drug demonstrates a clinical benefit to patients or an acceptable

safety profile, it could limit the indications for which a drug may be sold or revoke the drug’s marketing approval.

identification of certain side effects either during clinical trials or after a drug is on the market may result in reformulation

of a drug, additional pre-clinical and clinical trials, labeling changes, termination of ongoing clinical trials or withdrawal

Any of these events could delay or prevent us from generating revenue from the commercialization of these drugs and

cause us to incur significant additional costs.

Neither collaborators,

licensees nor we are permitted to market a product candidate in the United States until the particular product candidate is approved

for marketing by the FDA.

Specific pre-clinical data, chemistry, manufacturing and controls data, a proposed clinical trial protocol

and other information must be submitted to the FDA as part of an IND application, and clinical trials may commence only after the

IND application becomes effective.

To market a new drug in the United States, we must submit to the FDA and obtain FDA approval

An NDA must be supported by extensive clinical and pre-clinical data, as well as extensive information regarding chemistry,

manufacturing and controls, to demonstrate the safety and effectiveness of the product candidate, and the FDA will also assess

whether the manufacturing processes and facilities are suitable to support the application.

Approval of an NDA may be delayed due

to delays in FDA’s review of the manufacturing facility, which may require an onsite inspection.

Obtaining approval

of an NDA can be a lengthy, expensive and uncertain process.

Review time can be impacted by the quality of the information included

in the application, FDA’s internal resources such as the availability of reviewers, or requests from the FDA for additional

Failure to comply with

applicable regulatory requirements may, either before or after product approval, subject us to administrative or judicially imposed sanctions

that may negatively impact the approval of one or more of our product candidates or otherwise negatively impact our business.

with such regulations may consume substantial financial and management resources and expose us and our collaborators to the potential

for other adverse circumstances.

For example, a regulatory authority can place restrictions on the sale or marketing of a drug in order

to manage the risks identified during initial clinical trials or after the drug is on the market.

A regulatory authority can condition

the approval for a drug on costly post-marketing follow-up studies.

Based on these studies, if a regulatory authority does not believe

that the drug demonstrates a clinical benefit to patients or an acceptable safety profile, it could limit the indications for which a

drug may be sold or revoke the drug’s marketing approval.

In addition, identification of certain side effects either during clinical

trials or after a drug is on the market may result in reformulation of a drug, additional pre-clinical and clinical trials, labeling

changes, termination of ongoing clinical trials or withdrawal of approval.

Any of these events could delay or prevent us from generating

revenue from the commercialization of these drugs and cause us to incur significant additional costs.

Neither collaborators, licensees

nor we are permitted to market a product candidate in the United States until the particular product candidate is approved for marketing

Specific pre-clinical data, chemistry, manufacturing and controls data, a proposed clinical trial protocol and other information

must be submitted to the FDA as part of an IND application, and clinical trials may commence only after the IND application becomes effective.

To market a new drug in the United States, we must submit to the FDA and obtain FDA approval of an NDA.

An NDA must be supported by extensive

clinical and pre-clinical data, as well as extensive information regarding chemistry, manufacturing and controls, to demonstrate the

safety and effectiveness of the product candidate, and the FDA will also assess whether the manufacturing processes and facilities are

suitable to support the application.

Approval of an NDA may be delayed due to delays in FDA’s review of the manufacturing facility,

which may require an onsite inspection.

Obtaining approval of an

NDA can be a lengthy, expensive and uncertain process.

Review time can be impacted by the quality of the information included in the

application, FDA’s internal resources such as the availability of reviewers, or requests from the FDA for additional information.

Regulatory approval of an NDA is not guaranteed.

The number and types of pre-clinical studies and clinical trials

that will be required for FDA approval varies depending on the product candidate, the disease or condition that the product candidate

is designed to target and the regulations applicable to any particular product candidate.

Despite the time and expense exerted

in pre-clinical and clinical studies, failure can occur at any stage, and we could encounter problems that delay our product candidate

development or that cause us to abandon clinical trials or to repeat or perform additional pre-clinical studies and clinical trials.

The FDA can delay, limit or deny approval of a product candidate for many reasons, and product candidate development programs

may be delayed or may not be successful for many reasons including but not limited to, the following:

The FDA or IRBs may not authorize us to commence, amend, or continue clinical studies;

we may not be able to enroll a sufficient number of qualified patients for clinical trials in a timely manner or at all, patients may drop out of our clinical trials or be lost to follow-up at a higher rate than we anticipate, patients may not follow the clinical trial procedures, or the number of patients required for clinical trials may be larger than we anticipate;

the FDA may not accept an NDA or other submission due to, among other reasons, the content or formatting of the submission;

a product candidate may not be deemed adequately safe or effective for an intended use;

the FDA may not find the data from pre-clinical studies and clinical trials sufficient;

the FDA may require that we conduct additional pre-clinical or clinical studies, change our manufacturing process, or gather additional manufacturing information above what we currently have planned for;

the FDA’s interpretation and our interpretation of data from pre-clinical studies and clinical trials or chemistry, manufacturing and controls data may differ significantly;

the FDA may not agree with our intended indications, the design of our clinical or pre-clinical studies, or there may be a flaw in the design that does not become apparent until the studies are well advanced;

we may not be able to establish agreements with contractors or collaborators or they or we may fail to comply with applicable FDA and other regulatory requirements, including those identified in other risk factors;

the FDA may not accept aspects of our proposed labeling, or may impose specific limitations in the labeling and require post-marking commitments or Phase 4 clinical trials before the labeling can be expanded;

the FDA may determine that the manufacturing processes and facilities for our product candidate do not have sufficient good manufacturing practice (GMP) controls in place to support approval;

the FDA may change its approval policies or adopt new regulations.

Our pre-clinical and

clinical data, other information and procedures relating to a product candidate may not be sufficient to support approval by the

The number and types of pre-clinical studies and clinical trials that will be required

for FDA approval varies depending on the product candidate, the disease or condition that the product candidate is designed to target

and the regulations applicable to any particular product candidate.

Despite the time and expense exerted in pre-clinical and clinical

studies, failure can occur at any stage, and we could encounter problems that delay our product candidate development or that cause us

to abandon clinical trials or to repeat or perform additional pre-clinical studies and clinical trials.

The FDA can delay, limit or deny

approval of a product candidate for many reasons, and product candidate development programs may be delayed or may not be successful

for many reasons including but not limited to, the following:

FDA or IRBs may not authorize us to commence, amend, or continue clinical studies;

may not be able to enroll a sufficient number of qualified patients for clinical trials in

a timely manner or at all, patients may drop out of our clinical trials or be lost to follow-up

at a higher rate than we anticipate, patients may not follow the clinical trial procedures,

or the number of patients required for clinical trials may be larger than we anticipate;

FDA may not accept an NDA or other submission due to, among other reasons, the content or

formatting of the submission;

product candidate may not be deemed adequately safe or effective for an intended use;

FDA may not find the data from pre-clinical studies and clinical trials sufficient;

FDA may require that we conduct additional pre-clinical or clinical studies, change our manufacturing

process, or gather additional manufacturing information above what we currently have planned

FDA’s interpretation and our interpretation of data from pre-clinical studies and clinical

trials or chemistry, manufacturing and controls data may differ significantly;

FDA may not agree with our intended indications, the design of our clinical or pre-clinical

studies, or there may be a flaw in the design that does not become apparent until the studies

are well advanced;

may not be able to establish agreements with contractors or collaborators or they or we may

fail to comply with applicable FDA and other regulatory requirements, including those identified

in other risk factors;

FDA may not accept aspects of our proposed labeling, or may impose specific limitations in

the labeling and require post-marking commitments or Phase 4 clinical trials before the labeling

can be expanded;

FDA may determine that the manufacturing processes and facilities for our product candidate

do not have sufficient good manufacturing practice (GMP) controls in place to support approval;

FDA may change its approval policies or adopt new regulations.

Our pre-clinical

and clinical data, other information and procedures relating to a product candidate may not be sufficient to support approval by the

FDA or any other U.S.

or foreign regulatory authority, or regulatory interpretation of these data and procedures may be unfavorable.

Failure to conduct required post-approval studies, or confirm a clinical benefit, will allow the FDA to withdraw the drug from

the market on an expedited basis.

Our business and reputation may be harmed by any failure or significant delay in receiving regulatory

approval for the sale of any drugs resulting from our product candidates.

As a result, we cannot predict when or whether regulatory

approval will be obtained for any drug we develop.

Additionally, other

factors may serve to delay, limit or prevent the final approval by regulatory authorities of our product candidates for commercial

use, including, but not limited to:

we or our licensees will need to conduct significant clinical testing and development work to demonstrate the quality, safety, and efficacy of these product candidates before applications for marketing can be filed with the FDA, or with the regulatory authorities of other countries;

development and testing of product formulation, including identification of suitable excipients, or chemical additives intended to facilitate delivery of our product candidates;

Failure to conduct required post-approval studies, or confirm a clinical benefit, will allow the FDA to withdraw the drug from the market

on an expedited basis.

Our business and reputation may be harmed by any failure or significant delay in receiving regulatory approval

for the sale of any drugs resulting from our product candidates.

As a result, we cannot predict when or whether regulatory approval will

be obtained for any drug we develop.

Additionally, other factors

may serve to delay, limit or prevent the final approval by regulatory authorities of our product candidates for commercial use, including,

but not limited to:

or our licensees will need to conduct significant clinical testing and development work to

demonstrate the quality, safety, and efficacy of these product candidates before applications

for marketing can be filed with the FDA, or with the regulatory authorities of other countries;

● development

and testing of product formulation, including identification of suitable excipients, or chemical

additives intended to facilitate delivery of our product candidates;

it may take us many years to complete the testing of our product candidates, and failure can occur at any stage of this process;

negative or inconclusive results or adverse medical events during a clinical trial could cause us to delay or terminate our development efforts;

The successful development

of any of these product candidates is uncertain and, accordingly, we may never commercialize any of these product candidates or

generate significant revenue.

development and commercialization of our products is uncertain.

development and commercialization of current and future product candidates is subject to the risks of failure and delay inherent

in the development of new pharmaceutical products, including but not limited to the following:

to produce positive data in pre-clinical and clinical trials;

in product development, pre-clinical and clinical testing, or manufacturing;

expenditures in product development, clinical testing, or manufacturing;

with securing the heparin supply chain;

● uncertainties

relating to, or changes in FDA view of, the appropriate product approval pathway;

to obtain treatment of a drug or application under expedited development and review programs

or to obtain marketing exclusivities;

to receive or maintain regulatory approvals;

of superior or equivalent products;

to manufacture our product candidates on a commercial scale on our own, or in collaboration

with third parties;

to comply with a broad range of post-marketing requirements including those related to

labeling, promotion and advertising, manufacturing and quality, pharmacovigilance and

adverse event reporting, commercial distribution and supply chain requirements, and drug

sample distribution requirements;

to achieve market acceptance.

of these risks, our development efforts may not result in any commercially viable products.

If a significant portion of these

development efforts are not successfully completed, required regulatory approvals are not obtained or any approved products are

not commercialized successfully, our business, financial condition, and results of operations will be materially harmed.

inspection delay given the FDA’s current backlog of foreign inspections.

successful development of any of these product candidates is uncertain and, accordingly, we may never commercialize any of these product

candidates or generate significant revenue.

Successful development and commercialization of our products

is uncertain.

development and commercialization of current and future product candidates is subject to the risks of failure and delay inherent in the

development of new pharmaceutical products, including but not limited to the following:

● inability to produce

positive data in pre-clinical and clinical trials;

● delays in product development,

pre-clinical and clinical testing, or manufacturing;

● unplanned expenditures

in product development, clinical testing, or manufacturing;

● challenges with securing

the heparin supply chain;

● uncertainties relating

to, or changes in FDA view of, the appropriate product approval pathway;

● failure to obtain treatment

of a drug or application under expedited development and review programs or to obtain marketing

exclusivities;

● failure to receive

or maintain regulatory approvals;

● emergence of superior

or equivalent products;

● inability to manufacture

our product candidates on a commercial scale on our own, or in collaboration with third parties;

● failure to comply with

a broad range of post-marketing requirements including those related to labeling, promotion

and advertising, manufacturing and quality, pharmacovigilance and adverse event reporting,

commercial distribution and supply chain requirements, and drug sample distribution requirements;

● failure to achieve

market acceptance.

Because of these risks, our development efforts

may not result in any commercially viable products.

If a significant portion of these development efforts are not successfully completed,

required regulatory approvals are not obtained or any approved products are not commercialized successfully, our business, financial

condition, and results of operations will be materially harmed.

If we fail to comply with environmental,

health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could harm our business.

From time to time and

in the future, our operations may involve the use of hazardous and flammable materials, including chemicals and biological materials,

and may also produce hazardous waste.

Even if we contract with third parties for the disposal of these materials and waste, we

cannot completely eliminate the risk of contamination or injury resulting from these materials.

In the event of contamination or

injury resulting from the use or disposal of our hazardous materials, we could be held liable for any resulting damages, and any

liability could exceed our resources.

We also could incur significant costs associated with civil or criminal fines and penalties

for failure to comply with such laws and regulations.

In addition, we may

incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations.

or future environmental laws and regulations may impair our research, development or production efforts.

In addition, failure to

comply with these laws and regulations may result in substantial fines, penalties or other sanctions.

The successful commercialization

of DefenCath will depend on obtaining coverage and reimbursement for use of DefenCath from third-party payors.

Sales of pharmaceutical

products largely depend on the reimbursement of patients’ medical expenses by government health care programs and/or private

health insurers, both in the U.S.

Further, significant uncertainty exists as to the reimbursement status of newly approved

health care products.

We initially expect to sell DefenCath directly to hospitals and key dialysis center operators, but also plan

to expand its usage into oncology and total parenteral nutrition patients requiring catheters.

All of these potential customers

are healthcare providers who depend upon reimbursement by government and commercial insurance payors for dialysis and other treatments.

Depending on the treatment setting, we believe that DefenCath would be eligible for coverage under various reimbursement programs,

such as the End Stage Renal Disease (“ESRD”) Prospective Payment System and ESRD Quality Incentive Program;

coverage by any of these reimbursement programs is not assured, and even if coverage is granted, it could later be revoked or modified

under future regulations.

From time to time and in

the future, our operations may involve the use of hazardous and flammable materials, including chemicals and biological materials, and

may also produce hazardous waste.

Even if we contract with third parties for the disposal of these materials and waste, we cannot completely

eliminate the risk of contamination or injury resulting from these materials.

In the event of contamination or injury resulting from

the use or disposal of our hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our

We also could incur significant costs associated with civil or criminal fines and penalties for failure to comply with such

laws and regulations.

In addition, we may incur

substantial costs in order to comply with current or future environmental, health and safety laws and regulations.

Current or future

environmental laws and regulations may impair our research, development or production efforts.

In addition, failure to comply with these

laws and regulations may result in substantial fines, penalties or other sanctions.

The successful commercialization of DefenCath

will depend on obtaining coverage and reimbursement for use of DefenCath from third-party payors.

Sales of pharmaceutical products

largely depend on the reimbursement of patients’ medical expenses by government health care programs and/or private health insurers,

both in the U.S.

Further, significant uncertainty exists as to the reimbursement status of newly approved health care products.

We initially expect to sell DefenCath directly to hospitals and key dialysis center operators, but also plan to expand its usage into

oncology and total parenteral nutrition patients requiring catheters.

All of these potential customers are healthcare providers who depend

upon reimbursement by government and commercial insurance payors for dialysis and other treatments.

Depending on the treatment setting,

we believe that DefenCath would be eligible for coverage under various reimbursement programs, such as the End Stage Renal Disease (“ESRD”)

Prospective Payment System and ESRD Quality Incentive Program;

however, coverage by any of these reimbursement programs is not assured,

and even if coverage is granted, it could later be revoked or modified under future regulations.

Further, the U.S.

Centers for Medicare & Medicaid Services (“CMS”), which administers

Medicare, and works with states to administer Medicaid, has adopted and will continue to adopt and/or amend rules governing reimbursement

for specific treatments.

We anticipate that CMS and private insurers will increasingly demand that manufacturers demonstrate the

cost effectiveness of their products as part of the reimbursement review and approval process.

Rising healthcare costs have also

led many European and other foreign countries to adopt healthcare reform proposals and medical cost containment measures.

legislation could be introduced in the U.S.

Any measures affecting the reimbursement programs of these governmental and private

insurance payors, including any uncertainty in the medical community regarding their nature and effect on reimbursement programs,

could have an adverse effect on purchasing decisions regarding DefenCath, as well as limit the prices we may charge for DefenCath.

The failure to obtain or maintain reimbursement coverage for DefenCath or any other products could materially harm our operations.

In anticipation that

the CMS and private payers will demand that we demonstrate the cost effectiveness of DefenCath as part of the reimbursement review

and approval process, we will incorporate health economic evaluations into our clinical studies to support this review in the context

of the prospective use of DefenCath in dialysis, oncology and total parenteral nutrition settings.

However, our studies might not

be sufficient to support coverage or reimbursement at levels that allow providers to use DefenCath.

Physicians and patients may not accept and use

our products.

Even with the CE Mark

approval of Neutrolin, and even if we receive FDA or other foreign regulatory approval for DefenCath/Neutrolin or other product

candidates, physicians and patients may not accept and use our products.

Acceptance and use of our products will depend upon a

number of factors including the following:

perceptions by members of the health care community, including physicians, about the safety and effectiveness of our drug or device product;

prevalence of the disease to be treated;

prevalence and severity of any side effects;

cost-effectiveness of our product relative to competing products;

availability of coverage and reimbursement from government and other third-party payers;

timing of market introduction of our drugs and competitive drugs;

effectiveness of marketing and distribution efforts by us and our licensees and distributors, if any;

potential or perceived advantages or disadvantages over alternative treatments;

potential post-marketing commitments imposed by regulatory authorities, such as patient registries;

price of our future products, both in absolute terms and relative to alternative treatments;

the effect of current and future healthcare laws and regulations on our product candidates.

Because we expect sales

of DefenCath to generate substantially all of our product revenues for the foreseeable future, the failure of DefenCath to find

market acceptance would harm our business and would require us to seek additional financing.

in funding for the FDA and other government agencies or future government shutdowns or disruptions could cause delays in the submission

and regulatory review of marketing applications, which could negatively impact our business or prospects.

ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and

funding levels, ability to hire and retain key personnel and accept submission, applications, and the payment of user fees, and

statutory, regulatory, and policy changes.

In addition, government funding of other government agencies that fund research and

development activities is subject to the political process, which is inherently fluid and unpredictable.

The impact of global

events, including terrorism, natural disasters and pandemics, including the ongoing COVID-19 pandemic or other health emergencies,

may also cause disruptions in the normal functioning of the FDA or other government agencies.

Disruptions at the

FDA and other agencies may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies,

which would adversely affect our business.

For example, over the last several years, including for 35 days beginning on December

22, 2018, the U.S.

government has shut down several times and certain regulatory agencies, such as the FDA, had to furlough critical

FDA employees and stop critical activities.

In addition, in March 2020, the FDA announced the postponement of most foreign inspections

due to the global impact of COVID-19, which has continued for more than a year.

If a prolonged government shutdown or other disruption

to the normal functioning of government agencies occurs, it could significantly impact the ability of the FDA to timely review

and process our regulatory submissions, which could have a material adverse effect on our business or prospects.

At this time,

there is a backlog at FDA in conducting pre-approval inspections of manufacturing facilities, because of travel restrictions imposed

Such backlog has prevented the FDA from inspecting the facilities of our CMO for the manufacturing of DefenCath, which

is located outside the United States.

If FDA deems a pre-approval inspection to be necessary for approval of the DefenCath NDA,

there will be a delay until FDA inspectors can resume travel.

outbreak of the novel coronavirus disease, COVID-19, or other pandemic, epidemic or outbreak of an infectious disease may materially

and adversely impact our business, including our preclinical studies and clinical trials.

In December 2019, the

novel coronavirus disease, COVID-19, was identified in Wuhan, China.

This virus has been declared a pandemic and has spread to

multiple global regions.

The outbreak and government measures taken in response have also had a significant impact, both direct

and indirect, on businesses and commerce, as worker shortages have occurred;

Centers for Medicare

& Medicaid Services (“CMS”), which administers Medicare, and works with states to administer Medicaid, has adopted and

will continue to adopt and/or amend rules governing reimbursement for specific treatments.

We anticipate that CMS and private insurers

will increasingly demand that manufacturers demonstrate the cost effectiveness of their products as part of the reimbursement review

and approval process.

Rising healthcare costs have also led many European and other foreign countries to adopt healthcare reform proposals

and medical cost containment measures.

Similar legislation could be introduced in the U.S.

Any measures affecting the reimbursement programs

of these governmental and private insurance payors, including any uncertainty in the medical community regarding their nature and effect

on reimbursement programs, could have an adverse effect on purchasing decisions regarding DefenCath, as well as limit the prices we may

charge for DefenCath.

The failure to obtain or maintain reimbursement coverage for DefenCath or any other products could materially harm

our operations.

In anticipation that the

CMS and private payers will demand that we demonstrate the cost effectiveness of DefenCath as part of the reimbursement review and approval

process, we will incorporate health economic evaluations into our clinical studies to support this review in the context of the prospective

use of DefenCath in dialysis, oncology and total parenteral nutrition settings.

However, our studies might not be sufficient to support

coverage or reimbursement at levels that allow providers to use DefenCath.

Physicians and patients may not accept

and use our products.

Even with the CE Mark approval

of Neutrolin, and even if we receive FDA or other foreign regulatory approval for DefenCath/Neutrolin or other product candidates, physicians

and patients may not accept and use our products.

Acceptance and use of our products will depend upon a number of factors including the

● perceptions

by members of the health care community, including physicians, about the safety and effectiveness

of our drug or device product;

of the disease to be treated;

and severity of any side effects;

● cost-effectiveness

of our product relative to competing products;

● availability

of coverage and reimbursement from government and other third-party payers;

of market introduction of our drugs and competitive drugs;

● effectiveness

of marketing and distribution efforts by us and our licensees and distributors, if any;

or perceived advantages or disadvantages over alternative treatments;

post-marketing commitments imposed by regulatory authorities, such as patient registries;

of our future products, both in absolute terms and relative to alternative treatments;

effect of current and future healthcare laws and regulations on our product candidates.

we expect sales of DefenCath to generate substantially all of our product revenues for the foreseeable future, the failure of DefenCath

to find market acceptance would harm our business and would require us to seek additional financing.

Changes in funding for the FDA and other government agencies

or future government shutdowns or disruptions could cause delays in the submission and regulatory review of marketing applications, which

could negatively impact our business or prospects.

The ability of the FDA to review and approve new

products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel

and accept submission, applications, and the payment of user fees, and statutory, regulatory, and policy changes.

In addition, government

funding of other government agencies that fund research and development activities is subject to the political process, which is inherently

fluid and unpredictable.

The impact of global events, including terrorism, natural disasters and pandemics, including the ongoing COVID-19

pandemic or other health emergencies, may also cause disruptions in the normal functioning of the FDA or other government agencies.

Disruptions at the FDA and other agencies may also

slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our

For example, over the last several years, including for 35 days beginning on December 22, 2018, the U.S.

government has shut

down several times and certain regulatory agencies, such as the FDA, had to furlough critical FDA employees and stop critical activities.

In addition, in March 2020, the FDA announced the postponement of most foreign inspections due to the global impact of COVID-19, which

has continued for more than a year.

If a prolonged government shutdown or other disruption to the normal functioning of government agencies

occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have

a material adverse effect on our business or prospects.

At this time, there is a backlog at FDA in conducting pre-approval inspections

of manufacturing facilities, because of ongoing travel restrictions imposed by COVID-19.

Such backlog has prevented the FDA from inspecting

the facilities of our CMO for the manufacturing of DefenCath, which is located outside the United States.

If FDA deems a pre-approval

inspection to be necessary for approval of the DefenCath NDA, there will be a delay until FDA inspectors can resume travel.

The ongoing COVID-19 pandemic, or other pandemic,

epidemic or outbreak of an infectious disease may materially and adversely impact our business, including our preclinical studies and

clinical trials.

Global health concerns relating to the COVID-19

pandemic and related government actions to reduce the spread of the virus have had a significant impact, both direct and indirect, on

businesses and commerce, as worker shortages have occurred;

supply chains have been disrupted;

facilities and

production have been suspended;

and demand for certain goods and services, such as medical services and supplies, has spiked, while

demand for other goods and services, such as travel, has fallen.

In response to the COVID-19 outbreak, “shelter in place”

orders and other public health guidance measures have been implemented across much of the United States, Europe and Asia, including

in the locations of our offices, clinical trial sites, key vendors and partners.

Such “shelter in place” orders were

previously lifted, at least partially, in many locations.

However, an increase in the spread of COVID-19 and variants, which may

reflect the spread of one or more successive waves of the virus, has led to the re-imposition by many states of quarantine requirements

for out-of-state travelers and may lead to the re-imposition of “shelter-in-place” or other similar orders.

several vaccines for prevention or mitigation of the severity of the virus have been granted Emergency Use Authorization by the

FDA and foreign regulatory authorities, the timely distribution and public acceptance thereof in reducing the pandemic remain uncertain.

Our clinical development program timelines may be negatively affected by COVID-19, which could materially and adversely affect

our business, financial condition and results of operations.

Further, due to “shelter in place” orders and other public

health guidance measures, we have implemented a work-from-home policy for all staff members excluding those necessary to maintain

minimum basic operations.

Our increased reliance on personnel working from home may negatively impact productivity, or disrupt,

delay or otherwise adversely impact our business.

a result of the COVID-19 outbreak, or similar pandemics, and related travel restrictions and “shelter in place” orders

and other public health guidance measures, we have and may in the future experience disruptions that could materially and adversely

impact our clinical trials, business, financial condition and results of operations.

Potential disruptions include but are not

or difficulties at our third-party vendors on whom we are dependent for manufacturing

or difficulties in enrolling patients in our clinical trials;

or difficulties in initiating or expanding clinical trials, including delays or difficulties

with clinical site initiation and recruiting clinical site investigators and clinical

rates of patients withdrawing from our clinical trials following enrollment as a result

of contracting COVID-19 or other health conditions or being forced to quarantine;

of healthcare resources away from the conduct of clinical trials, including the diversion

of hospitals serving as our clinical trial sites and hospital staff supporting the conduct

of our clinical trials;

● interruption

of key clinical trial activities, such as clinical trial site data monitoring, due to

limitations on travel imposed or recommended by federal or state governments, employers

and others or interruption of clinical trial subject visits and study procedures, which

may impact the integrity of subject data and clinical study endpoints;

● interruption

or delays in the operations of the FDA or other regulatory authorities, which may impact

review and approval timelines for our NDA;

or disruptions in preclinical experiments and investigational new drug application-enabling

studies due to restrictions of on-site staff and unforeseen circumstances at contract

research organizations and vendors;

● interruption

of, or delays in receiving supplies of our product candidates from our contract manufacturing

organizations due to staffing shortages, production slowdowns or stoppages and disruptions

in delivery systems;

● limitations

on our ability to recruit and hire key personnel due to our inability to meet with candidates

because of travel restrictions and “shelter in place” orders;

● limitations

on employee resources that would otherwise be focused on the conduct of our preclinical

studies and clinical trials, including because of sickness of employees or their families

or the desire of employees to avoid contact with large groups of people;

● interruption

or delays to our sourced discovery and clinical activities.

COVID-19 pandemic continues to rapidly evolve.

The extent to which the outbreak impacts our business, preclinical studies and

clinical trials will depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as

the ultimate geographic spread of the disease, the duration of the pandemic, travel restrictions and social distancing in the

United States and other countries, business closures or business disruptions and the effectiveness of actions taken in the United

States and other countries to contain and treat the disease.

If we or any of the third parties with whom we engage were to experience

shutdowns or other business disruptions, our ability to conduct our business in the manner and on the timelines presently planned

could be materially and negatively impacted.

addition, the trading prices for our common stock and other biopharmaceutical companies have been highly volatile as a result

of the COVID-19 pandemic.

As a result, we may face difficulties raising capital through sales of our common stock or such sales

may be on unfavorable terms.

trials required for our product candidates may be expensive and time-consuming, and their outcome is uncertain.

facilities and production have been suspended;

and demand for certain goods and services, such as medical services and supplies, has spiked, while demand for other goods and services,

such as travel, has fallen.

In response to the COVID-19 outbreak, governmental authorities implementing numerous measures to try to contain

the virus, including travel bans and restrictions, quarantines, “shelter-in-place” orders, and business limitations and shutdowns

across much of the United States, Europe and Asia, including in the locations of our offices, clinical trial sites, key vendors and partners.

Such “shelter in place” orders were previously lifted, at least partially, in many locations.

However, an increase in the

spread of COVID-19 and variants, including the Delta and Omicron variants, which may affect the spread or severity of one or more successive

waves of the virus, has led, and may continue to lead, to the re-imposition by many nations and the U.S.

of quarantine requirements for

travelers from other regions and may lead to the re-imposition of “shelter-in-place” or other similar orders.

Although several

vaccines for prevention or mitigation of the severity of the virus have been granted Emergency Use Authorization by the FDA and foreign

regulatory authorities, the timely distribution, public acceptance and effectiveness thereof in reducing the pandemic remain uncertain.

If an onsite inspection of the third-party manufacturing facility of our contract manufacturer is required for the satisfactory resolution

of issues required for approval of the DefenCath NDA, the Company may encounter additional delays in obtaining FDA approval because the

FDA is currently facing a backlog due to the COVID-19 pandemic.

Our clinical development program timelines may be negatively affected

by COVID-19, which could materially and adversely affect our business, financial condition and results of operations.

Further, due to

“shelter in place” orders and other public health guidance measures, we have implemented a work-from-home policy for all staff

members excluding those necessary to maintain minimum basic operations.

Our increased reliance on personnel working from home may negatively

impact productivity, or disrupt, delay or otherwise adversely impact our business.

Furthermore, a widespread return of in-person workplace

or commercial activities could lead to a resurgence of the virus.

As a result of the COVID-19 outbreak, or similar

pandemics, and related travel restrictions and “shelter in place” orders and other public health guidance measures, we have

and may in the future experience disruptions that could materially and adversely impact our clinical trials, business, financial condition

and results of operations.

Potential disruptions include but are not limited to:

● delays or difficulties

at our third-party vendors on whom we are dependent for manufacturing activities;

● delays or difficulties

in enrolling patients in our clinical trials;

● delays or difficulties

in initiating or expanding clinical trials, including delays or difficulties with clinical

site initiation and recruiting clinical site investigators and clinical site staff;

● increased rates of

patients withdrawing from our clinical trials following enrollment as a result of contracting

COVID-19 or other health conditions or being forced to quarantine;

● diversion of healthcare

resources away from the conduct of clinical trials, including the diversion of hospitals

serving as our clinical trial sites and hospital staff supporting the conduct of our clinical

● interruption of key

clinical trial activities, such as clinical trial site data monitoring, due to limitations

on travel imposed or recommended by federal or state governments, employers and others or

interruption of clinical trial subject visits and study procedures, which may impact the

integrity of subject data and clinical study endpoints;

● interruption or delays

in the operations of the FDA or other regulatory authorities, including a halt in on-site

inspections, which may impact review and approval timelines for our NDA;

● delays or disruptions

in preclinical experiments and investigational new drug application-enabling studies due

to restrictions of on-site staff and unforeseen circumstances at contract research organizations

● interruption of, or

delays in receiving supplies of our product candidates from our contract manufacturing organizations

due to staffing shortages, production slowdowns or stoppages and disruptions in delivery

● limitations on our

ability to recruit and hire key personnel due to our inability to meet with candidates because

of travel restrictions and “shelter in place” orders;

● limitations on employee

resources that would otherwise be focused on the conduct of our preclinical studies and clinical

trials, including because of sickness of employees or their families or the desire of employees

to avoid contact with large groups of people;

● interruption or delays

to our sourced discovery and clinical activities.

The COVID-19 pandemic continues to rapidly evolve.

The extent to which the outbreak impacts our business, preclinical studies and clinical trials will depend on future developments, which

are highly uncertain and cannot be predicted with confidence, such as the ultimate geographic spread of the disease, the severity of

any new variations of the virus, the duration of the pandemic, travel restrictions and social distancing in the United States and other

countries, business closures or business disruptions and the effectiveness of actions taken in the United States and other countries

to contain and treat the disease.

If we or any of the third parties with whom we engage were to experience shutdowns or other business

disruptions, our ability to conduct our business in the manner and on the timelines presently planned could be materially and negatively

In addition, the trading prices for our common

stock and other biopharmaceutical companies have been highly volatile as a result of the COVID-19 pandemic.

As a result, we may face

difficulties raising capital through sales of our common stock or such sales may be on unfavorable terms.

Clinical trials required for our product candidates may be expensive

and time-consuming, and their outcome is uncertain.

order to obtain FDA or foreign approval to market a new drug or device product, we must demonstrate proof of safety and effectiveness

3 unchanged sentences

Conducting clinical trials is a lengthy, time-consuming, and expensive process.

length of time may vary substantially according to the type, complexity, novelty, and intended use of the product candidate, and

often can be several years or more per trial.

Delays associated with the DefenCath development program or the development plans

for any other product candidates may cause us to incur additional operating expenses.

The commencement and rate of completion

of clinical trials may be delayed by many factors, including, for example:

to manufacture sufficient quantities of qualified materials under the FDA’s cGMP

requirements for use in clinical trials;

than expected rates of patient recruitment;

to recruit a sufficient number of patients;

● modification

of clinical trial protocols;

in regulatory requirements for clinical trials;

of effectiveness during clinical trials;

of unforeseen safety issues;

suspension, or termination of clinical trials due to the IRB responsible for overseeing

the study at a particular study site;

or regulatory delays or “clinical holds” requiring suspension or termination

of the trials.

the results from early pre-clinical and clinical trials are not necessarily predictive of results to be obtained in later clinical

Accordingly, even if we obtain positive results from early pre-clinical or clinical trials, we may not achieve the same

success in later clinical trials.

Moreover, comparisons of results across different studies should be viewed with caution as such

comparisons are limited by a number of factors, including differences in study designs and populations.

Such comparisons also

will not provide a sufficient basis for any comparative claims following product approval.

Clinical results are frequently susceptible

to varying interpretations that may delay, limit or prevent regulatory approvals or commercialization.

Negative or inconclusive

results or adverse medical events during a clinical trial could cause a clinical trial to be delayed, repeated or terminated,

or a clinical program to be abandoned.

clinical trials may be conducted in patients with serious or life-threatening diseases for whom conventional treatments have been

unsuccessful or for whom no conventional treatment exists, and in some cases, our product is expected to be used in combination

with approved therapies that themselves have significant adverse event profiles.

During the course of treatment, these patients

could suffer adverse medical events or die for reasons that may or may not be related to our products.

We cannot ensure that safety

issues will not arise with respect to our products in clinical development.

trials may not demonstrate statistically significant safety and effectiveness to obtain the requisite regulatory approvals for

product candidates.

The failure of clinical trials to demonstrate safety and effectiveness for the desired indications could harm

the development of our product candidates.

Such a failure could cause us to abandon a product candidate and could delay development

of other product candidates.

Any delay in, or termination of, our clinical trials would delay the filing of any NDA or any Premarket

Approval Application, or PMA, with the FDA and, ultimately, our ability to commercialize our product candidates and generate product

Any change in, or termination of, our clinical trials could materially harm our business, financial condition, and results

of operations.

we fail to comply with international regulatory requirements, we could be subject to regulatory delays, fines or other penalties.

of time may vary substantially according to the type, complexity, novelty, and intended use of the product candidate, and often can be

several years or more per trial.

Delays associated with the DefenCath development program or the development plans for any other product

candidates may cause us to incur additional operating expenses.

The commencement and rate of completion of clinical trials may be delayed

by many factors, including, for example:

● inability to manufacture

sufficient quantities of qualified materials under the FDA’s cGMP requirements for

use in clinical trials;

● slower than expected

rates of patient recruitment;

● failure to recruit

a sufficient number of patients;

● modification of clinical

trial protocols;

● changes in regulatory

requirements for clinical trials;

● lack of effectiveness

during clinical trials;

● emergence of unforeseen

safety issues;

● delays, suspension,

or termination of clinical trials due to the IRB responsible for overseeing the study at

a particular study site;

● government or regulatory

delays or “clinical holds” requiring suspension or termination of the trials.

Further, the results from early pre-clinical

and clinical trials are not necessarily predictive of results to be obtained in later clinical trials.

Accordingly, even if we obtain

positive results from early pre-clinical or clinical trials, we may not achieve the same success in later clinical trials.

comparisons of results across different studies should be viewed with caution as such comparisons are limited by a number of factors,

including differences in study designs and populations.

Such comparisons also will not provide a sufficient basis for any comparative

claims following product approval.

Clinical results are frequently susceptible to varying interpretations that may delay, limit or prevent

regulatory approvals or commercialization.

Negative or inconclusive results or adverse medical events during a clinical trial could cause

a clinical trial to be delayed, repeated or terminated, or a clinical program to be abandoned.

Our clinical trials may be conducted in patients

with serious or life-threatening diseases for whom conventional treatments have been unsuccessful or for whom no conventional treatment

exists, and in some cases, our product is expected to be used in combination with approved therapies that themselves have significant

adverse event profiles.

During the course of treatment, these patients could suffer adverse medical events or die for reasons that may

or may not be related to our products.

We cannot ensure that safety issues will not arise with respect to our products in clinical development.

Clinical trials may not demonstrate statistically

significant safety and effectiveness to obtain the requisite regulatory approvals for product candidates.

The failure of clinical trials

to demonstrate safety and effectiveness for the desired indications could harm the development of our product candidates.

Such a failure

could cause us to abandon a product candidate and could delay development of other product candidates.

Any delay in, or termination of,

our clinical trials would delay the filing of any NDA or any Premarket Approval Application, or PMA, with the FDA and, ultimately, our

ability to commercialize our product candidates and generate product revenues.

Any change in, or termination of, our clinical trials

could materially harm our business, financial condition, and results of operations.

If we fail to comply with international regulatory

requirements we could be subject to regulatory delays, fines or other penalties.

requirements in foreign countries for international sales of medical devices often vary from country to country.

The occurrence

and related impact of the following factors would harm our business:

in receipt of, or failure to receive, foreign regulatory approvals or clearances;

loss of previously obtained approvals or clearances;

failure to comply with existing or future regulatory requirements.

CE Mark is a mandatory conformity mark for products to be sold in the European Economic Area.

Currently, 28 countries in Europe

require products to bear CE Marking.

To market in Europe, a product must first obtain the certifications necessary to affix the

The CE Mark is an international symbol of adherence to the Medical Device Regulations, previously the Medical Device

Directives, and the manufacturer’s declaration that the product complies with essential requirements.

Compliance with these

requirements is ascertained within a certified Quality Management System (QMS) pursuant to ISO 13485.

In order to obtain and to

maintain a CE Mark, a product must be in compliance with the applicable quality assurance provisions of the aforementioned ISO

and obtain certification of its quality assurance systems by a recognized European Union notified body.

We received CE Mark approval

for Neutrolin on July 5, 2013.

However, certain individual countries within the European Union require further approval by their

national regulatory agencies.

Additionally, implementation of the new European Union Medical Device Regulations may pose challenges

in demonstrating continued conformity to the new medical device regulatory paradigm.

Failure to receive or maintain these other

requisite approvals could prohibit us from marketing and selling Neutrolin in the entire European Economic Area or elsewhere.

do not have, and may never obtain, the regulatory approvals we need to market our product candidates outside of the European Union.

we have received the CE Mark approval for Neutrolin in Europe, certain individual countries within the European Union require

further approval by their national regulatory agencies.

Failure to receive or maintain these other requisite approvals could prohibit

us from marketing and selling Neutrolin in the entire European Economic Area.

In addition, we will need regulatory approval to

market and sell Neutrolin in foreign countries outside of Europe.

In the United States,

we have not received the regulatory approvals required for the commercial sale of any of our product candidates.

The NDA for DefenCath

could not be approved by FDA in its present form and resolution of deficiencies at our third-party manufacturing facility is required.

Additionally, the FDA is requiring a manual extraction study to demonstrate that the labeled volume can be consistently withdrawn

from the vials despite an existing in-process control to demonstrate fill volume within specifications.

We plan to meet with the

FDA to discuss proposed resolutions to the deficiencies, but we may not be able to obtain regulatory approval for commercial distribution.

also are pursuing development of taurolidine-based devices for several indications, including wound closure, surgical meshes,

and wound management.

The FDA regards taurolidine as a new chemical entity and therefore an unapproved new drug.

Consequently,

there is no appropriate predicate device currently marketed in the U.S.

on which a 510(k) approval process for these devices could

As a result, we will be required to submit a premarket approval application for marketing authorization for these indications.

In the event that the NDA for DefenCath is approved by the FDA, the regulatory pathway for these devices can be revisited with

Although there will presumably still be no appropriate predicate, de novo Class II designation can be proposed,

based on a risk assessment and a reasonable assurance of safety and effectiveness.

is possible that DefenCath will not receive any further approval or that any of our other product candidates will be approved

for marketing.

Failure to obtain regulatory approvals, or delays in obtaining regulatory approvals, would adversely affect the

successful commercialization of DefenCath or any other drugs or products that we or our partners develop, impose additional costs

on us or our collaborators, diminish any competitive advantages that we or our partners may attain, and/or adversely affect our

cash flow, financial condition and results of operations.

if approved, our products will be subject to extensive post-approval regulation.

The occurrence and related

impact of the following factors would harm our business:

● delays in receipt of,

or failure to receive, foreign regulatory approvals or clearances;

● the loss of previously

obtained approvals or clearances;

● the failure to comply

with existing or future regulatory requirements.

The CE Mark is a mandatory conformity mark

for products to be sold in the European Economic Area.

Currently, 28 countries in Europe require products to bear CE Marking.

in Europe, a product must first obtain the certifications necessary to affix the CE Mark.

The CE Mark is an international symbol

of adherence to the Medical Device Regulations, previously the Medical Device Directives, and the manufacturer’s declaration that

the product complies with essential requirements.

Compliance with these requirements is ascertained within a certified Quality Management

System (QMS) pursuant to ISO 13485.

In order to obtain and to maintain a CE Mark, a product must be in compliance with the applicable

quality assurance provisions of the aforementioned ISO and obtain certification of its quality assurance systems by a recognized European

Union notified body.

We received CE Mark approval for Neutrolin on July 5, 2013.

However, certain individual countries within the European

Union require further approval by their national regulatory agencies.

Additionally, implementation of the new European Union Medical

Device Regulations may pose challenges in demonstrating continued conformity to the new medical device regulatory paradigm.

Failure to receive

or maintain these other requisite approvals could prohibit us from marketing and selling Neutrolin in the entire European Economic

Area or elsewhere.

We do not have, and may never obtain, the regulatory approvals

we need to market our product candidates outside of the European Union.

While we have received the CE Mark approval for

Neutrolin in Europe, certain individual countries within the European Union require further approval by their national regulatory agencies.

Failure to receive or maintain these other requisite approvals could prohibit us from marketing and selling Neutrolin

in the entire European Economic Area.

In addition, we will need regulatory approval to market and sell Neutrolin in foreign countries

outside of Europe.

In the United States, we have not received the

regulatory approvals required for the commercial sale of any of our product candidates.

The NDA for DefenCath could not be approved by

FDA in its present form and resolution of deficiencies at our third-party manufacturing facility is required.

Additionally, the FDA is

requiring a manual extraction study to demonstrate that the labeled volume can be consistently withdrawn from the vials despite an existing

in-process control to demonstrate fill volume within specifications.

We met with the FDA to discuss proposed resolutions to the deficiencies,

but we may not be able to obtain regulatory approval for commercial distribution.

We also are pursuing development of taurolidine-based

devices for several indications, including wound closure, surgical meshes, and wound management.

The FDA regards taurolidine as a new

chemical entity and therefore an unapproved new drug.

Consequently, there is no appropriate predicate device currently marketed in the

on which a 510(k) approval process for these devices could be based.

As a result, we will be required to submit a premarket approval

application for marketing authorization for these indications.

In the event that the NDA for DefenCath is approved by the FDA, the regulatory

pathway for these devices can be revisited with the FDA.

Although there will presumably still be no appropriate predicate, de

novo Class II designation can be proposed, based on a risk assessment and a reasonable assurance of safety and effectiveness.

It is possible that DefenCath will not receive

any further approval or that any of our other product candidates will be approved for marketing.

Failure to obtain regulatory approvals,

or delays in obtaining regulatory approvals, would adversely affect the successful commercialization of DefenCath or any other drugs

or products that we or our partners develop, impose additional costs on us or our collaborators, diminish any competitive advantages

that we or our partners may attain, and/or adversely affect our cash flow, financial condition and results of operations.

Even if approved, our products will be subject to extensive

post-approval regulation.

a product is approved, numerous post-approval requirements apply in the United States and abroad.

These include, among other things,

requirements related to pharmacovigilance and adverse event and other reporting, supply chain security requirements, suspect and

illegitimate product investigations and notifications, limitations on product advertising and promotion and on the distribution

of product samples, and ongoing adherence to cGMPs, as well as the need to submit appropriate new or supplemental applications

and obtain FDA approval for certain changes to the approved product, product labeling, or manufacturing process.

and maintaining systems and procedures for compliance with these requirements, and for training and monitoring personnel relative

to their compliance, is expensive, time consuming, and an ongoing effort.

Depending on the circumstances, failure to meet these

post-approval requirements can result in criminal prosecution, fines, injunctions, recall or seizure of products, total or partial

suspension of production, denial or withdrawal of pre-marketing product approvals, or refusal to allow us to enter into supply

contracts, including government contracts.

In addition, even if we comply with FDA, foreign and other requirements, new information

regarding the safety or effectiveness of a product could lead the FDA or a foreign regulatory body to modify or withdraw product

Related to Our Business and Industry

and technological change may make our product candidates and technologies less attractive or obsolete.

compete with established pharmaceutical and medical device companies that are pursuing other forms of prevention or treatment

for the same or similar indications we are pursuing and that have greater financial and other resources.

Other companies may succeed

in developing products earlier than we do, obtaining FDA or any other regulatory agency approval for products more rapidly, or

developing products that are more effective than our product candidates.

Research and development by others may render our technology

or product candidates obsolete or noncompetitive, or result in processes, treatments or cures superior to any therapy we develop.

We face competition from companies that internally develop competing technology or acquire competing technology from universities

and other research institutions.

As these companies develop their technologies, they may develop competitive positions that may

prevent, make futile, or limit our product commercialization efforts, which would result in a decrease in the revenue we would

be able to derive from the sale of any products.

can be no assurance that DefenCath or any other product candidate will be accepted by the marketplace as readily as these or other

competing treatments.

Furthermore, if our competitors’ products are approved before ours, it could be more difficult for

us to obtain approval from the FDA or any other regulatory agency.

Even if our products are successfully developed and approved

for use by all governing regulatory bodies, there can be no assurance that physicians and patients will accept any of our products

as a treatment of choice.

the pharmaceutical and medical device industry is diverse, complex, and rapidly changing.

By its nature, the business risks associated

with the industry are numerous and significant.

The effects of competition, intellectual property disputes, market acceptance,

and FDA or other regulatory agency regulations preclude us from forecasting regulatory approval, product acceptance, revenues

or income with certainty or even confidence.

policy changes, including reimbursement policies for drugs and medical devices, may have an adverse effect on our business, financial

requirements related to pharmacovigilance and adverse event and other reporting, supply chain security requirements, suspect and illegitimate

product investigations and notifications, limitations on product advertising and promotion and on the distribution of product samples,

and ongoing adherence to cGMPs, as well as the need to submit appropriate new or supplemental applications and obtain FDA approval for

certain changes to the approved product, product labeling, or manufacturing process.

Establishing and maintaining systems and procedures

for compliance with these requirements, and for training and monitoring personnel relative to their compliance, is expensive, time consuming,

and an ongoing effort.

Depending on the circumstances, failure to meet these post-approval requirements can result in criminal prosecution,

fines, injunctions, recall or seizure of products, total or partial suspension of production, denial or withdrawal of pre-marketing product

approvals, or refusal to allow us to enter into supply contracts, including government contracts.

In addition, even if we comply with

FDA, foreign and other requirements, new information regarding the safety or effectiveness of a product could lead the FDA or a foreign

regulatory body to modify or withdraw product approval.

Risks Related to Our Business and Industry

Competition and technological change may make our product candidates

and technologies less attractive or obsolete.

compete with established pharmaceutical and medical device companies that are pursuing other forms of prevention or treatment for the

same or similar indications we are pursuing and that have greater financial and other resources.

Other companies may succeed in developing

products earlier than we do, obtaining FDA or any other regulatory agency approval for products more rapidly, or developing products

that are more effective than our product candidates.

Research and development by others may render our technology or product candidates

obsolete or noncompetitive, or result in processes, treatments or cures superior to any therapy we develop.

We face competition from

companies that internally develop competing technology or acquire competing technology from universities and other research institutions.

As these companies develop their technologies, they may develop competitive positions that may prevent, make futile, or limit our product

commercialization efforts, which would result in a decrease in the revenue we would be able to derive from the sale of any products.

There can be no assurance that DefenCath or any

other product candidate will be accepted by the marketplace as readily as these or other competing treatments.

Furthermore, if our competitors’

products are approved before ours, it could be more difficult for us to obtain approval from the FDA or any other regulatory agency.

Even if our products are successfully developed and approved for use by all governing regulatory bodies, there can be no assurance that

physicians and patients will accept any of our products as a treatment of choice.

Furthermore, the pharmaceutical and medical device

industry is diverse, complex, and rapidly changing.

By its nature, the business risks associated with the industry are numerous and significant.

The effects of competition, intellectual property disputes, market acceptance, and FDA or other regulatory agency regulations preclude

us from forecasting regulatory approval, product acceptance, revenues or income with certainty or even confidence.

Healthcare policy changes, including reimbursement policies

for drugs and medical devices, may have an adverse effect on our business, financial condition and results of operations.

Our future revenues, profitability and access

to capital will be affected by the continuing efforts of governmental and private third-party payors to manage, contain or reduce the

costs of health care through various means, such as capping prices, limiting price increases, reducing reimbursement, and requiring rebates.

Market acceptance and sales of DefenCath or any other product candidates that we develop will depend on reimbursement policies and may

be affected by health care reform measures in the U.S.

Government authorities and other third-party payors, such as private

health insurers, decide which drugs they will pay for and establish reimbursement levels.

We cannot be sure that reimbursement will be

available for DefenCath or any other product candidates that we develop.

Also, we cannot be sure that the amount of reimbursement available,

if any, will not reduce the demand for, or the price of, our products.

If reimbursement is not available or is available only at limited

levels, we may not be able to successfully commercialize DefenCath or any other product candidates that we develop.

In both the U.S.

and certain foreign jurisdictions,

there have been and we expect there will continue to be a number of legislative and regulatory changes to the health care system that

could affect our ability to sell our approved products profitably.

government and other governments have shown significant interest

in pursuing healthcare reform.

In particular, the Medicare Modernization Act of 2003 revised the payment methodology for many products

under the Medicare program in the United States.

This has resulted in lower rates of reimbursement.

In 2010, the Patient Protection and

Affordable Care Act, as amended by the Health Care and Education Reconciliation Act (collectively, the “Affordable Care Act”),

The Affordable Care Act substantially changed the way healthcare is financed by both governmental and private insurers.

Such government-adopted reform measures may adversely affect the pricing of healthcare products and services in the U.S.

or internationally

and the amount of reimbursement available from governmental agencies or other third-party payors.

In recent years, the U.S.

Congress has sought

to repeal and has significantly amended the Affordable Care Act.

We expect that there will continue to be proposals by legislators at

both the federal and state levels, regulators and third-party payors to keep healthcare costs down while expanding individual healthcare

Certain of these changes could impose limitations on the prices we will be able to charge for any products that are approved

or the amounts of reimbursement available for these products from governmental agencies or other third-party payors or may increase the

tax requirements for life sciences companies such as ours.

Any such legislation could have an adverse effect on our business, financial

condition and results of operations.

future revenues, profitability and access to capital will be affected by the continuing efforts of governmental and private third-party

payors to manage, contain or reduce the costs of health care through various means, such as capping prices, limiting price increases,

reducing reimbursement, and requiring rebates.

Market acceptance and sales of DefenCath or any other product candidates that we

develop will depend on reimbursement policies and may be affected by health care reform measures in the U.S.

authorities and other third-party payors, such as private health insurers, decide which drugs they will pay for and establish

reimbursement levels.

We cannot be sure that reimbursement will be available for DefenCath or any other product candidates that

Also, we cannot be sure that the amount of reimbursement available, if any, will not reduce the demand for, or the

price of, our products.

If reimbursement is not available or is available only at limited levels, we may not be able to successfully

commercialize DefenCath or any other product candidates that we develop.

both the U.S.

and certain foreign jurisdictions, there have been and we expect there will continue to be a number of legislative

and regulatory changes to the health care system that could affect our ability to sell our approved products profitably.

government and other governments have shown significant interest in pursuing healthcare reform.

In particular, the Medicare Modernization

Act of 2003 revised the payment methodology for many products under the Medicare program in the United States.

This has resulted

in lower rates of reimbursement.

In 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education

Reconciliation Act (collectively, the “Affordable Care Act”), was enacted.

The Affordable Care Act substantially changed

the way healthcare is financed by both governmental and private insurers.

Such government-adopted reform measures may adversely

affect the pricing of healthcare products and services in the U.S.

or internationally and the amount of reimbursement available

from governmental agencies or other third-party payors.

recent years, the U.S.

Congress has sought to repeal and has significantly amended the Affordable Care Act.

We expect that there

will continue to be proposals by legislators at both the federal and state levels, regulators and third-party payors to keep healthcare

costs down while expanding individual healthcare benefits.

Certain of these changes could impose limitations on the prices we

will be able to charge for any products that are approved or the amounts of reimbursement available for these products from governmental

agencies or other third-party payors or may increase the tax requirements for life sciences companies such as ours.

Any such legislation

could have an adverse effect on our business, financial condition and results of operations.

has been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which

have resulted in several recent Congressional inquiries and proposed and enacted bills by Congress and the states designed to,

among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient

programs, and reform government program reimbursement methodologies for products.

There has been heightened governmental scrutiny

over the manner in which manufacturers set prices for their marketed products, which have resulted in several recent Congressional inquiries

and proposed and enacted bills by Congress and the states designed to, among other things, bring more transparency to product pricing,

review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies

for products.

In addition, the U.S.

government, state legislatures,

and foreign governments have shown significant interest in implementing cost containment programs, including price-controls, restrictions

on reimbursement and requirements for substitution of generic products for branded prescription drugs to limit the growth of government

paid health care costs.

government, state legislatures, and foreign governments have shown significant interest in implementing

cost containment programs, including price-controls, restrictions on reimbursement and requirements for substitution of generic products

for branded prescription drugs to limit the growth of government paid health care costs.

For example, the U.S.

government has passed legislation requiring pharmaceutical manufacturers to provide

rebates and discounts to certain entities and governmental payors to participate in federal healthcare programs.

Further, Congress

and the current administration have each indicated that it will continue to seek new legislative and/or administrative measures

to control drug costs, and the current administration recently released a “Blueprint”, or plan, to reduce the cost

government has passed

legislation requiring pharmaceutical manufacturers to provide rebates and discounts to certain entities and governmental payors to participate

in federal healthcare programs.

Further, Congress and the current administration have each indicated that it will continue to seek new

legislative and/or administrative measures to control drug costs, and the current administration recently released a “Blueprint”,

or plan, to reduce the cost of drugs.

The current administration’s Blueprint contains certain measures that the U.S.

Department of Health and Human

Services is already working to implement.

Individual states in the United States have also been increasingly passing legislation

and implementing regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints,

discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases,

designed to encourage importation from other countries and bulk purchasing.

administration authorities in countries other than the U.S.

may not provide reimbursement for Neutrolin or any of our other product

candidates at rates sufficient for us to achieve profitability, or at all.

Like the U.S., these countries could adopt health care

reform proposals and could materially alter their government-sponsored health care programs by reducing reimbursement rates.

reduction in reimbursement rates under Medicare or private insurers or foreign health care programs could negatively affect the

pricing of our products.

If we are not able to charge a sufficient amount for our products, then our margins and our profitability

will be adversely affected.

we lose key management or scientific personnel, cannot recruit qualified employees, directors, officers, or other personnel or

experience increases in compensation costs, our business may materially suffer.

are highly dependent on the principal members of our management and scientific staff, specifically, Khoso Baluch, a director and

our Chief Executive Officer, Dr.

Matthew David, our Executive Vice President and Chief Financial Officer, Phoebe Mounts, our Executive

Vice President and General Counsel, Paul Chew, our Acting Chief Medical Officer, Elizabeth Masson-Hurlburt, our Executive Vice

President and Head of Clinical Operations, and John Armstrong, our Executive Vice President for Technical Operations.

success will depend in part on our ability to identify, hire, and retain current and additional personnel.

We experience intense

competition for qualified personnel and may be unable to attract and retain the personnel necessary for the development of our

Moreover, our work force is located in the New York metropolitan area, where competition for personnel with the scientific

and technical skills that we seek is extremely high and is likely to remain high.

Because of this competition, our compensation

costs may increase significantly.

In addition, we have only limited ability to prevent former employees from competing with us.

we are unable to hire additional qualified personnel, our ability to grow our business may be harmed.

time, we expect to hire additional qualified personnel with expertise in government regulation, formulation and manufacturing,

and sales and marketing, among others.

We compete for qualified individuals with numerous pharmaceutical companies, universities

and other research institutions.

Competition for such individuals is intense, and we cannot be certain that our search for such

personnel will be successful.

of Health and Human Services is already working to implement.

Individual states in the United States have also been increasingly passing

legislation and implementing regulations designed to control pharmaceutical product pricing, including price or patient reimbursement

constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some

cases, designed to encourage importation from other countries and bulk purchasing.

Health administration authorities in countries

other than the U.S.

may not provide reimbursement for Neutrolin or any of our other product candidates at rates sufficient for us to

achieve profitability, or at all.

Like the U.S., these countries could adopt health care reform proposals and could materially alter

their government-sponsored health care programs by reducing reimbursement rates.

Any reduction in reimbursement rates under Medicare

or private insurers or foreign health care programs could negatively affect the pricing of our products.

If we are not able to charge

a sufficient amount for our products, then our margins and our profitability will be adversely affected.

If we lose key management or scientific personnel, cannot recruit

qualified employees, directors, officers, or other personnel or experience increases in compensation costs, our business may materially

We are highly dependent on the principal members

of our management and scientific staff, specifically, Dr.

Matthew David, our interim Chief Executive Officer, Executive Vice President

and Chief Financial Officer, Phoebe Mounts, our Executive Vice President and General Counsel, Elizabeth Masson-Hurlburt, our Executive

Vice President and Head of Clinical Operations and Thomas Nusbickel, our Chief Commercial Officer.

Our future success will depend in part

on our ability to identify, hire, and retain current and additional personnel.

We experience intense competition for qualified personnel

and may be unable to attract and retain the personnel necessary for the development of our business.

Moreover, our work force is located

in the New York metropolitan area, where competition for personnel with the scientific and technical skills that we seek is extremely

high and is likely to remain high.

Because of this competition, our compensation costs may increase significantly.

In addition, we have

only limited ability to prevent former employees from competing with us.

If we are unable to hire additional qualified personnel, our

ability to grow our business may be harmed.

time, we expect to hire additional qualified personnel with expertise in government regulation, formulation and manufacturing, and sales

and marketing, among others.

We compete for qualified individuals with numerous pharmaceutical companies, universities and other research

institutions.

Competition for such individuals is intense, and we cannot be certain that our search for such personnel will be successful.

Attracting and retaining such qualified personnel will be critical to our success.

may not successfully manage our growth.

success will depend upon the expansion of our operations to commercialize DefenCath and the effective management of any growth,

which could place a significant strain on our management and our administrative, operational and financial resources.

this growth, we may need to expand our facilities, augment our operational, financial and management systems and hire and train

additional qualified personnel.

We may not successfully manage our growth.

success will depend upon the expansion of our operations to commercialize DefenCath and the effective management of any growth, which

could place a significant strain on our management and our administrative, operational and financial resources.

To manage this growth,

we may need to expand our facilities, augment our operational, financial and management systems and hire and train additional qualified

If we are unable to manage our growth effectively, our business may be materially harmed.

face the risk of product liability claims and the amount of insurance coverage we hold now or in the future may not be adequate

to cover all liabilities we might incur.

We face the risk of product liability claims and the amount

of insurance coverage we hold now or in the future may not be adequate to cover all liabilities we might incur.

business exposes us to the risk of product liability claims that are inherent in the development of drugs.

If the use of one or

more of our or our collaborators’ drugs or devices harms people, we may be subject to costly and damaging product liability

claims brought against us by clinical trial participants, consumers, health care providers, pharmaceutical companies or others

selling our products.

currently carry product liability insurance.

We cannot predict all of the possible harms or side effects that may result and,

therefore, the amount of insurance coverage we hold may not be adequate to cover all liabilities we might incur.

Our insurance

covers bodily injury and property damage arising from our clinical trials, subject to industry-standard terms, conditions and

If the use of one or more

of our or our collaborators’ drugs or devices harms people, we may be subject to costly and damaging product liability claims brought

against us by clinical trial participants, consumers, health care providers, pharmaceutical companies or others selling our products.

We currently carry product liability insurance.

We cannot predict all of the possible harms or side effects that may result and, therefore, the amount of insurance coverage we hold

may not be adequate to cover all liabilities we might incur.

Our insurance covers bodily injury and property damage arising from our

clinical trials, subject to industry-standard terms, conditions and exclusions.

Our coverage also includes the sale of commercial products.

We have expanded our insurance coverage to include the

sale of commercial products due to the receipt of the CE Mark approval, but we may be unable to maintain such coverage or obtain

commercially reasonable product liability insurance for any other products approved for marketing.

we are unable to obtain insurance at an acceptable cost or otherwise protect against potential product liability claims, we may

be exposed to significant liabilities, which may materially and adversely affect our business and financial position.

sued for any injury allegedly caused by our or our collaborators’ products and do not have sufficient insurance coverage,

our liability could exceed our total assets and our ability to pay the liability.

A successful product liability claim or series

of claims brought against us would decrease our cash and could cause the value of our capital stock to decrease.

may be exposed to liability claims associated with the use of hazardous materials and chemicals.

research, development and manufacturing activities and/or those of our third-party contractors may involve the controlled use

We have expanded our insurance coverage to include the sale of commercial products due to the receipt of the CE Mark approval, but we

may be unable to maintain such coverage or obtain commercially reasonable product liability insurance for any other products approved

for marketing.

If we are unable to obtain insurance at an acceptable

cost or otherwise protect against potential product liability claims, we may be exposed to significant liabilities, which may materially

and adversely affect our business and financial position.

If we are sued for any injury allegedly caused by our or our collaborators’

products and do not have sufficient insurance coverage, our liability could exceed our total assets and our ability to pay the liability.

A successful product liability claim or series of claims brought against us would decrease our cash and could cause the value of our

capital stock to decrease.

We may be exposed to liability claims associated with the use

of hazardous materials and chemicals.

Although we believe that our safety procedures for using, storing, handling and disposing

of these materials comply with federal, state and local, as well as foreign, laws and regulations, we cannot completely eliminate

the risk of accidental injury or contamination from these materials.

In the event of such an accident, we and the third-party

could be held liable for any resulting damages and any liability could materially adversely affect our business, financial condition

and results of operations.

In addition, the federal, state and local, as well as foreign, laws and regulations governing the use,

manufacture, storage, handling and disposal of hazardous or radioactive materials and waste products may require us to incur substantial

compliance costs that could materially adversely affect our business, financial condition and results of operations.

and global economic conditions may pose challenges to our business strategy, which relies on funding from the financial markets

or collaborators.

conditions in the U.S.

or global economy, including financial markets, may adversely affect our business and the business of current

and prospective vendors, licensees and collaborators, and others with whom we do or may conduct business.

research, development and manufacturing activities and/or those of our third-party contractors may involve the controlled use of hazardous

materials and chemicals.

Although we believe that our safety procedures for using, storing, handling and disposing of these materials

comply with federal, state and local, as well as foreign, laws and regulations, we cannot completely eliminate the risk of accidental

injury or contamination from these materials.

In the event of such an accident, we and the third-party could be held liable for any resulting

damages and any liability could materially adversely affect our business, financial condition and results of operations.

the federal, state and local, as well as foreign, laws and regulations governing the use, manufacture, storage, handling and disposal

of hazardous or radioactive materials and waste products may require us to incur substantial compliance costs that could materially adversely

affect our business, financial condition and results of operations.

Negative U.S.

and global economic conditions may pose challenges

to our business strategy, which relies on funding from the financial markets or collaborators.

Negative conditions in the U.S.

or global economy,

may experience disruptions as the result of international hostilities, natural disasters, pandemics, other international health

emergencies, or weather-related or similar events (such as fires, hurricanes, earthquakes, floods, landslides and other natural

conditions including the effects of climate change), political instability, labor strikes or turmoil, or terrorist attacks.

particular, countries around the world have experienced the spread of the COVID-19 pandemic, resulting in quarantines, supply

chain disruptions, reduction in travel, increased demand for medical services and a general decline in economic activity and market

Similar potential disruptions may occur in the future in any of the locations in which we or our collaborators do

We continue to assess the potential impact on our counterparties and customers of such events, and what impact, if any,

these events could have on our business.

duration and severity of these conditions is uncertain.

If negative economic conditions occur, we may be unable to secure funding

on terms satisfactory to us to sustain our operations or to find suitable collaborators to advance our internal programs, even

if we achieve positive results from our drug development programs.

Related to Our Intellectual Property

we materially breach or default under any of our license agreements, the licensor party to such agreement will have the right

to terminate the license agreement, which termination may materially harm our business.

including financial markets, may adversely affect our business and the business of current and prospective vendors, licensees and collaborators,

and others with whom we do or may conduct business.

or global economy may experience disruptions as the result of international

hostilities, natural disasters, pandemics, other international health emergencies, or weather-related or similar events (such as fires,

hurricanes, earthquakes, floods, landslides and other natural conditions including the effects of climate change), political instability,

labor strikes or turmoil, or terrorist attacks.

In particular, countries around the world have experienced the spread of the COVID-19

pandemic, resulting in quarantines, supply chain disruptions, reduction in travel, increased demand for medical services and a general

decline in economic activity and market confidence.

Similar potential disruptions may occur in the future in any of the locations in

which we or our collaborators do business.

We continue to assess the potential impact on our counterparties and customers of such events,

and what impact, if any, these events could have on our business.

The duration and severity of these conditions

is uncertain.

If negative economic conditions occur, we may be unable to secure funding on terms satisfactory to us to sustain our operations

or to find suitable collaborators to advance our internal programs, even if we achieve positive results from our drug development programs.

Risks Related to Our Intellectual Property

If we materially breach or default under any of our license

agreements, the licensor party to such agreement will have the right to terminate the license agreement, which termination may materially

harm our business.

commercial success will depend in part on the maintenance of our license agreements.

Each of our license agreements provides the

licensor with a right to terminate the license agreement for our material breach or default under the agreement, including the

failure to make any required milestone or other payments.

Should the licensor under any of our license agreements exercise such

a termination right, we would lose our right to the intellectual property under the respective license agreement, which loss may

materially harm our business.

we and our licensors do not obtain protection for and successfully defend our respective intellectual property rights, competitors

may be able to take advantage of our research and development efforts to develop competing products.

commercial success will depend in part on obtaining further patent protection for our products, product candidates and other technologies

and successfully defending any patents that we currently have or will obtain against third-party challenges.

The patents which

we currently believe are most material to our business are as follows:

8,541,393 (expiring November 2, 2024) (the “Prosl Patent”) - use

of Neutrolin for preventing infection and maintenance of catheter patency in hemodialysis

Each of our license agreements provides the licensor

with a right to terminate the license agreement for our material breach or default under the agreement, including the failure to make

any required milestone or other payments.

Should the licensor under any of our license agreements exercise such a termination right,

we would lose our right to the intellectual property under the respective license agreement, which loss may materially harm our business.

If we and our licensors do not obtain protection for and successfully

defend our respective intellectual property rights, competitors may be able to take advantage of our research and development efforts

to develop competing products.

Our commercial success will depend in part

on obtaining further patent protection for our products, product candidates and other technologies and successfully defending any patents

that we currently have or will obtain against third-party challenges.

The patents which we currently believe are most material to our

business are as follows:

(expiring November 2, 2024) (the “Prosl Patent”) - use of Neutrolin for preventing

infection and maintenance of catheter patency in hemodialysis catheters;

(expiring November 2, 2024);

(expiring May 16, 2025);

Patent EP 1 814 562 B1 (expiring October 12, 2025) (the “Prosl European Patent”)

- a low heparin catheter lock solution for maintaining and preventing infection in a

hemodialysis catheter.

The European Patent Office has found the Prosl European Patent

to be invalid and has revoked it.

● European Patent EP

1 814 562 B1 (expiring October 12, 2025) (the “Prosl European Patent”) - a low

heparin catheter lock solution for maintaining and preventing infection in a hemodialysis

The European Patent Office has found the Prosl European Patent to be invalid

and has revoked it.

An appeal to that decision is pending.

are currently seeking further patent protection for our compounds and methods of treating diseases.

However, the patent process

is subject to numerous risks and uncertainties, and there can be no assurance that we will be successful in protecting our products

by obtaining and defending patents.

These risks and uncertainties include the following:

that may be issued or licensed may be challenged, invalidated, or circumvented, or otherwise

may not provide any competitive advantage;

competitors, many of which have substantially greater resources than we have and many

of which have made significant investments in competing technologies, may seek, or may

already have obtained, patents that will limit, interfere with, or eliminate our ability

to make, use, and sell our potential products either in the United States or in international

may be significant pressure on the United States government and other international governmental

bodies to limit the scope of patent protection both inside and outside the United States

for treatments that prove successful as a matter of public policy regarding worldwide

health concerns;

other than the United States may have less restrictive patent laws than those upheld

by United States courts, allowing foreign competitors the ability to exploit these laws

to create, develop, and market competing products.

addition, the United States Patent and Trademark Office (“PTO”), and patent offices in other jurisdictions have often

required that patent applications concerning pharmaceutical and/or biotechnology-related inventions be limited or narrowed substantially

to cover only the specific innovations exemplified in the patent application, thereby limiting the scope of protection against

competitive challenges.

Thus, even if we or our licensors are able to obtain patents, the patents may be substantially narrower

than anticipated.

Additionally, the breadth of claims allowed in biotechnology and pharmaceutical patents or their enforceability

cannot be predicted.

We cannot be sure that, should any patents issue, we will be provided with adequate protection against potentially

competitive products.

Furthermore, we cannot be sure that should patents issue, they will be of commercial value to us, or that

private parties, including competitors, will not successfully challenge our patents or circumvent our patent position in the U.S.

above-mentioned patents are exclusively licensed to us.

To support our patent strategy, we have engaged in a review of patentability

and certain freedom to operate issues, including performing certain searches.

However, patentability and certain freedom to operate

issues are inherently complex, and we cannot provide assurances that a relevant patent office and/or relevant court will agree

with our conclusions regarding patentability issues or with our conclusions regarding freedom to operate issues, which can involve

subtle issues of claim interpretation and/or claim liability.

Furthermore, we may not be aware of all patents, published applications

or published literature that may affect our business either by blocking our ability to commercialize our product candidates, preventing

the patentability of our product candidates to us or our licensors, or covering the same or similar technologies that may invalidate

our patents, limit the scope of our future patent claims or adversely affect our ability to market our product candidates.

Additionally,

it is also possible that prior art of which we are aware, but which we do not believe affects the validity or enforceability of

a claim, may, nonetheless, ultimately be found by a court of law or an administration panel to affect the validity or enforceability

If a third party were to prevail on a legal assertion of invalidity and/or unenforceability, we would lose at least

part, and perhaps all, of the patent protection on our product candidates.

Such loss of patent protection could have a material

adverse impact on our business.

Additionally, since patent applications in the United States are maintained in secrecy until published

or issued and as publication of discoveries in the scientific or patent literature often lag behind the actual discoveries, we

cannot be certain that we were the first to make the inventions covered by the pending patent applications or issued patents referred

to above or that we were the first to file patent applications for such inventions.

addition to patents, we also rely on trade secrets and proprietary know-how.

Although we take measures to protect this information

by entering into confidentiality and inventions agreements with our employees, and some but not all of our scientific advisors,

consultants, and collaborators, we cannot provide any assurances that these agreements will not be breached, that we will be able

to protect ourselves from the harmful effects of disclosure or dispute ownership if they are breached, or that our trade secrets

will not otherwise become known or be independently discovered by competitors.

We may also be unsuccessful in executing such an

agreement with each party who in fact develops intellectual property that we regard as our own, which may result in claims by

or against us related to the ownership of such intellectual property.

If any of these events occurs, or we otherwise lose protection

for our trade secrets or proprietary know-how, the value of our intellectual property may be greatly reduced.

Even if we are successful

in prosecuting or defending against such claims, litigation could result in substantial costs and be a distraction to our senior

management and scientific personnel.

and future intellectual property disputes could require us to spend time and money to address such disputes and could limit our

intellectual property rights.

biotechnology and pharmaceutical industries have been characterized by extensive litigation regarding patents and other intellectual

property rights, and companies have employed intellectual property litigation to gain a competitive advantage.

We may initiate

or become subject to infringement claims or litigation arising out of patents and pending applications of our competitors, or

we may become subject to proceedings initiated by our competitors or other third parties or the PTO or applicable foreign bodies

to reexamine the patentability of our licensed or owned patents.

In addition, litigation may be necessary to enforce our issued

patents, to protect our trade secrets and know-how, or to determine the enforceability, scope, and validity of the proprietary

rights of others.

If we are required to defend patent infringement actions brought by third parties, or if we sue to protect our

own patent rights, we may be required to pay substantial litigation costs and managerial attention may be diverted from business

operations even if the outcome is not adverse to us.

In addition, any legal action that seeks damages or an injunction to stop

us from carrying on our commercial activities relating to the affected technologies could subject us to monetary liability and

We are currently seeking further patent protection

for our compounds and methods of treating diseases.

However, the patent process is subject to numerous risks and uncertainties, and there

can be no assurance that we will be successful in protecting our products by obtaining and defending patents.

These risks and uncertainties

include the following:

● patents that may be

issued or licensed may be challenged, invalidated, or circumvented, or otherwise may not

provide any competitive advantage;

● our competitors, many

of which have substantially greater resources than we have and many of which have made significant

investments in competing technologies, may seek, or may already have obtained, patents that

will limit, interfere with, or eliminate our ability to make, use, and sell our potential

products either in the United States or in international markets;

● there may be significant

pressure on the United States government and other international governmental bodies to limit

the scope of patent protection both inside and outside the United States for treatments that

prove successful as a matter of public policy regarding worldwide health concerns;

● countries other than

the United States may have less restrictive patent laws than those upheld by United States

courts, allowing foreign competitors the ability to exploit these laws to create, develop,

and market competing products.

In addition, the United States Patent and Trademark

Office (“PTO”), and patent offices in other jurisdictions have often required that patent applications concerning pharmaceutical

and/or biotechnology-related inventions be limited or narrowed substantially to cover only the specific innovations exemplified in the

patent application, thereby limiting the scope of protection against competitive challenges.

Thus, even if we or our licensors are able

to obtain patents, the patents may be substantially narrower than anticipated.

Additionally, the breadth of claims allowed in biotechnology

and pharmaceutical patents or their enforceability cannot be predicted.

We cannot be sure that, should any patents issue, we will be

provided with adequate protection against potentially competitive products.

Furthermore, we cannot be sure that should patents issue,

they will be of commercial value to us, or that private parties, including competitors, will not successfully challenge our patents or

circumvent our patent position in the U.S.

The above-mentioned patents are exclusively licensed

To support our patent strategy, we have engaged in a review of patentability and certain freedom to operate issues, including

performing certain searches.

However, patentability and certain freedom to operate issues are inherently complex, and we cannot provide

assurances that a relevant patent office and/or relevant court will agree with our conclusions regarding patentability issues or with

our conclusions regarding freedom to operate issues, which can involve subtle issues of claim interpretation and/or claim liability.

Furthermore, we may not be aware of all patents, published applications or published literature that may affect our business either by

blocking our ability to commercialize our product candidates, preventing the patentability of our product candidates to us or our licensors,

or covering the same or similar technologies that may invalidate our patents, limit the scope of our future patent claims or adversely

affect our ability to market our product candidates.

Additionally, it is also possible that prior art of which we are aware, but

which we do not believe affects the validity or enforceability of a claim, may, nonetheless, ultimately be found by a court of law or

an administration panel to affect the validity or enforceability of a claim.

If a third party were to prevail on a legal assertion of

invalidity and/or unenforceability, we would lose at least part, and perhaps all, of the patent protection on our product candidates.

Such loss of patent protection could have a material adverse impact on our business.

Additionally, since patent applications in

the United States are maintained in secrecy until published or issued and as publication of discoveries in the scientific or patent literature

often lag behind the actual discoveries, we cannot be certain that we were the first to make the inventions covered by the pending patent

applications or issued patents referred to above or that we were the first to file patent applications for such inventions.

In addition to patents, we also rely on trade

secrets and proprietary know-how.

Although we take measures to protect this information by entering into confidentiality and inventions

agreements with our employees, and some but not all of our scientific advisors, consultants, and collaborators, we cannot provide any

assurances that these agreements will not be breached, that we will be able to protect ourselves from the harmful effects of disclosure

or dispute ownership if they are breached, or that our trade secrets will not otherwise become known or be independently discovered by

We may also be unsuccessful in executing such an agreement with each party who in fact develops intellectual property that

we regard as our own, which may result in claims by or against us related to the ownership of such intellectual property.

If any of these

events occurs, or we otherwise lose protection for our trade secrets or proprietary know-how, the value of our intellectual property

may be greatly reduced.

Even if we are successful in prosecuting or defending against such claims, litigation could result

in substantial costs and be a distraction to our senior management and scientific personnel.

Ongoing and future intellectual property disputes could require

us to spend time and money to address such disputes and could limit our intellectual property rights.

The biotechnology and pharmaceutical industries

have been characterized by extensive litigation regarding patents and other intellectual property rights, and companies have employed

intellectual property litigation to gain a competitive advantage.

We may initiate or become subject to infringement claims or litigation

arising out of patents and pending applications of our competitors, or we may become subject to proceedings initiated by our competitors

or other third parties or the PTO or applicable foreign bodies to reexamine the patentability of our licensed or owned patents.

litigation may be necessary to enforce our issued patents, to protect our trade secrets and know-how, or to determine the enforceability,

scope, and validity of the proprietary rights of others.

If we are required to defend patent infringement actions brought by third parties,

or if we sue to protect our own patent rights, we may be required to pay substantial litigation costs and managerial attention may be

diverted from business operations even if the outcome is not adverse to us.

In addition, any legal action that seeks damages or an injunction

to stop us from carrying on our commercial activities relating to the affected technologies could subject us to monetary liability and

require us or any third party licensors to obtain a license to continue to use the affected technologies.

We cannot predict whether

we would prevail in any of these types of actions or that any required license would be made available on commercially acceptable

terms or at all.

Furthermore, to the extent that we or our consultants or research collaborators use intellectual property owned

by others in work performed for us, disputes may also arise as to the rights in such intellectual property or in resulting know-how

and inventions.

An adverse claim could subject us to significant liabilities to such other parties and/or require disputed rights

to be licensed from such other parties.

initiated court proceedings in Germany for patent infringement and unfair use of our proprietary information related to Neutrolin

We cannot predict whether we

would prevail in any of these types of actions or that any required license would be made available on commercially acceptable terms

Furthermore, to the extent that we or our consultants or research collaborators use intellectual property owned by others

in work performed for us, disputes may also arise as to the rights in such intellectual property or in resulting know-how and inventions.

An adverse claim could subject us to significant liabilities to such other parties and/or require disputed rights to be licensed from

such other parties.

We initiated court proceedings in Germany for

patent infringement and unfair use of our proprietary information related to Neutrolin (as described below).

We also have had opposition

proceedings brought against the European Patent and the German utility model patent which are the basis of our infringement proceedings

(as described below).

We also have had opposition proceedings brought against the European Patent and the German utility model

patent which are the basis of our infringement proceedings (as described below).

The defense and prosecution of these ongoing

and any future intellectual property suits, PTO or foreign proceedings, and related legal and administrative proceedings are costly

and time-consuming to pursue, and their outcome is uncertain.

An adverse determination in litigation or PTO or foreign proceedings

to which we may become a party could subject us to significant liabilities, including damages, require us to obtain licenses from

third parties, restrict or prevent us from selling our products in certain markets, or invalidate or render unenforceable our

licensed or owned patents.

Although patent and intellectual property disputes might be settled through licensing or similar arrangements,

the costs associated with such arrangements may be substantial and could include our paying large fixed payments and ongoing royalties.

The defense and prosecution of these ongoing and any future intellectual property suits, PTO or foreign proceedings,

and related legal and administrative proceedings are costly and time-consuming to pursue, and their outcome is uncertain.

determination in litigation or PTO or foreign proceedings to which we may become a party could subject us to significant liabilities,

including damages, require us to obtain licenses from third parties, restrict or prevent us from selling our products in certain markets,

or invalidate or render unenforceable our licensed or owned patents.

Although patent and intellectual property disputes might be settled

through licensing or similar arrangements, the costs associated with such arrangements may be substantial and could include our paying

large fixed payments and ongoing royalties.

Furthermore, the necessary licenses may not be available on satisfactory terms or at all.

September 9, 2014, we filed in the District Court of Mannheim, Germany a patent infringement action against TauroPharm GmbH and

Tauro-Implant GmbH as well as their respective CEOs (the “Defendants”) claiming infringement of our European Patent

EP 1 814 562 B1, which was granted by the European Patent Office (the “EPO”) on January 8, 2014 (the “Prosl

European Patent”).

The Prosl European Patent covers a low dose heparin catheter lock solution for maintaining patency and

preventing infection in a hemodialysis catheter.

On September 9, 2014, we filed in the District

Court of Mannheim, Germany a patent infringement action against TauroPharm GmbH and Tauro-Implant GmbH as well as their respective CEOs,

referred to as the Defendants claiming infringement of our European Patent EP 1 814 562 B1, which was granted by the EPO on January 8,

2014, or the Prosl European Patent.

The Prosl European Patent covers a low dose heparin catheter lock solution for maintaining patency

and preventing infection in a hemodialysis catheter.

In this action, we claim that the Defendants infringe on the Prosl European Patent

by manufacturing and distributing catheter locking solutions to the extent they are covered by the claims of the Prosl European

We believe that our patent is sound and are seeking injunctive relief and raising claims for information, rendering of

accounts, calling back, destruction and damages.

Separately, TauroPharm has filed an opposition with the EPO against the Prosl

European Patent alleging that it lacks novelty and inventive step.

We cannot predict the ultimate outcome of either of these related

At present, the EPO has revoked the Prosl European Patent as invalid, and we have filed an appeal, which is currently

the same complaint against the same Defendants, we also alleged an infringement (requesting the same remedies) of NDP’s

utility model DE 20 2005 022 124 U1 (the “Utility Model”), which we believe is fundamentally identical to the Prosl

European Patent in its main aspects and claims.

The Court separated the two proceedings and the Prosl European Patent and the

Utility Model were being tried separately.

TauroPharm has filed a cancellation action against the Utility Model before the German

Patent and Trademark Office (the “German PTO”) based on the similar arguments as those in the opposition against the

Prosl European Patent.

Court issued its decisions on May 8, 2015 staying both proceedings.

In its decisions, the Court found that the commercialization

by TauroPharm in Germany of its TauroLock catheter lock solutions Hep100 and Hep500 infringes both the Prosl European Patent and

the Utility Model and further that there is no prior use right that would allow TauroPharm to continue to make, use or sell its

product in Germany.

However, the Court declined to issue an injunction in favor of us that would preclude the continued commercialization

by TauroPharm based upon its finding that there is a sufficient likelihood that the EPO, in the case of the Prosl European Patent,

or the German PTO, in the case of the Utility Model, may find that such patent or utility model is invalid.

Specifically, the

Court noted the possible publication of certain instructions for product use that may be deemed to constitute prior art.

the District Court determined that it will defer any consideration of the request by us for injunctive and other relief until

such time as the EPO or the German PTO has ruled on the underlying validity of the Prosl European Patent and the Utility Model.

opposition proceeding against the Prosl European Patent before the EPO is ongoing.

Oral proceedings before the Opposition Division

at the EPO were held on November 25, 2015, at which the three-judge patent examiner panel considered arguments related to the

validity of the Prosl European Patent.

The hearing was adjourned due to the fact that the panel was of the view that Claus Herdeis,

one of the managing directors of TauroPharm, has to be heard as a witness in a further hearing in order to close some gaps in

the documentation presented by TauroPharm as regards the publication of prior art.

German PTO held a hearing in the validity proceedings relating to the Utility Model on June 29, 2016, at which the panel affirmed

its preliminary finding that the Utility Model was invalid based upon prior publication of a reference to the benefits that may

be associated with adding heparin to a taurolidine based solution.

The Company filed an appeal against the ruling on September

An oral hearing was held on September 17, 2019 in which the German Federal Patent affirmed the first instance decision

that the Utility Model was invalid.

The decision has only a declaratory effect, as the Utility Model had expired in November 2015.

On April 28, 2020, we filed a withdrawal of the complaint on the German utility model, thereby waiving our claims on these proceedings.

November 22, 2017, the EPO in Munich, Germany held a further oral hearing in this matter.

At the hearing, the panel held that

the Prosl European Patent would be invalidated because it did not meet the requirements of novelty based on a technical aspect

of the European intellectual property law.

We disagree with this decision and have appealed the decision.

We continue to believe

that the Prosl European Patent is indeed novel and that its validity should be maintained.

There can be no assurance that we will

prevail in this matter.

In addition, the ongoing Unfair Competition litigation against TauroPharm is not affected and will continue.

January 16, 2015, we filed a complaint against TauroPharm GmbH and its managing directors in the District Court of Cologne, Germany.

In the complaint, we allege violation of the German Unfair Competition Act by TauroPharm for the unauthorized use of its proprietary

information obtained in confidence by TauroPharm.

We allege that TauroPharm is improperly and unfairly using its proprietary information

relating to the composition and manufacture of Neutrolin, in the manufacture and sale of TauroPharm’s products TauroLockTM,

TauroLock-HEP100 and TauroLock-HEP500.

We seek a cease and desist order against TauroPharm from continuing to manufacture and

sell any product containing taurolidine (the active pharmaceutical ingredient (“API”) of Neutrolin) and citric acid

in addition to possible other components, damages for any sales in the past and the removal of all such products from the market.

An initial hearing in the District Court of Cologne, Germany was held on November 19, 2015 to consider our claims.

14, 2016, the court issued an interim decision in the form of a court order outlining several issues of concern that relate primarily

to court’s interest in clarifying the facts and reviewing any and all available documentation, in particular with regard

to the question which specific know-how was provided to TauroPharm by whom and when.

A further oral hearing in this matter was

held on November 15, 2016.

In this hearing, the court heard arguments from us and TauroPharm concerning the allegations of unfair

On March 7, 2017, the court issued another interim decision in the form of a court order outlining again several

issues relating to the argumentation of both sides in the proceedings.

Both parties submitted further writs in this matter and

the court scheduled a further hearing for May 8, 2018.

After having been rescheduled several times, the hearing took place on

November 20, 2018.

A decision was rendered by the court on December 11, 2018, dismissing the complaint in its entirety.

we intend to continue to pursue this matter, and still believe that our claims are well-founded.

We have therefore appealed in

January 2019 and filed our grounds of appeal in March 2019.

An oral hearing was held on September 6, 2019 in which our legal counsel

brought forward further arguments for the fact that the manufacturing process of the respective catheter locking solution is indeed

protectable as a trade secret.

In view of these new arguments, the court issued an evidentiary order on September 27, 2019 ordering

an expert opinion.

The expert opinion was not in our favor, but we have filed a response to the expert opinion in reaction to

which the Court asked the expert to supplement his opinion to address the issues brought forward in our submission.

In the supplementary

expert opinion, the expert confirmed his view.

We have filed another response and an oral hearing has been scheduled for February

5, 2021 but was postponed to June 18, 2021 due to the COVID-19 situation in Germany.

decisions by the European and German patent offices may affect patent rights in other jurisdictions.

prior art on the basis of which the Prosl European Patent and the German Utility Model have been found to be invalid may be

used to challenge the validity of issued United States and/or other foreign patents that are directed to the same or similar

subject matter, in a court action or in an administrative proceeding before the USPTO.

Pending United States and/or foreign

patent applications may be denied on that basis of that prior art as well.

by manufacturing and distributing catheter locking solutions to the extent they are covered by the claims of the Prosl European Patent.

We believe that our patent is sound and are seeking injunctive relief and raising claims for information, rendering of accounts, calling

back, destruction and damages.

Separately, TauroPharm has filed an opposition with the EPO against the Prosl European Patent alleging

that it lacks novelty and inventive step.

We cannot predict the ultimate outcome of either of these related matters.

At present, the

EPO has revoked the Prosl European Patent as invalid, and we have filed an appeal, which is currently pending.

In the same complaint against the same Defendants,

we also alleged an infringement (requesting the same remedies) of NDP’s utility model DE 20 2005 022 124 U1, referred to as the

Utility Model, which we believe is fundamentally identical to the Prosl European Patent in its main aspects and claims.

The Court separated

the two proceedings and the Prosl European Patent and the Utility Model claims were tried separately.

TauroPharm has filed a cancellation

action against the Utility Model before the German Patent and Trademark Office, or German PTO based on the similar arguments as those

in the opposition against the Prosl European Patent.

The Court issued its decisions on May 8, 2015,

staying both proceedings.

In its decisions, the Court found that the commercialization by TauroPharm in Germany of its TauroLock catheter

lock solutions Hep100 and Hep500 infringes both the Prosl European Patent and the Utility Model and further that there is no prior use

right that would allow TauroPharm to continue to make, use or sell its product in Germany.

However, the Court declined to issue an injunction

in favor of us that would preclude the continued commercialization by TauroPharm based upon its finding that there is a sufficient likelihood

that the EPO, in the case of the Prosl European Patent, or the German PTO, in the case of the Utility Model, may find that such patent

or utility model is invalid.

Specifically, the Court noted the possible publication of certain instructions for product use that may be

deemed to constitute prior art.

As such, the District Court determined that it will defer any consideration of the request by us for injunctive

and other relief until such time as the EPO or the German PTO made a final decision on the underlying validity of the Prosl European Patent

and the Utility Model.

The opposition proceeding against the Prosl European

Patent before the EPO is ongoing.

Oral proceedings before the Opposition Division at the EPO were held on November 25, 2015, at which

the three-judge patent examiner panel considered arguments related to the validity of the Prosl European Patent.

The hearing was adjourned

due to the fact that the panel was of the view that Claus Herdeis, one of the managing directors of TauroPharm, had to be heard as a

witness in a further hearing in order to close some gaps in the documentation presented by TauroPharm as regards the publication of prior

The German PTO held a hearing in the validity

proceedings relating to the Utility Model on June 29, 2016, at which the panel affirmed its preliminary finding that the Utility Model

was invalid based upon prior publication of a reference to the benefits that may be associated with adding heparin to a taurolidine based

We filed an appeal against the ruling on September 7, 2016.

An oral hearing was held on September 17, 2019 in which the German

Federal Patent Court affirmed the first instance decision that the Utility Model was invalid.

The decision has only a declaratory effect,

as the Utility Model had expired in November 2015.

On April 28, 2020, we filed a withdrawal of the complaint on the German utility model,

thereby waiving our claims on these proceedings.

On November 22, 2017, the EPO in Munich, Germany

held a further oral hearing in this matter.

At the hearing, the panel held that the Prosl European Patent would be invalidated because

it did not meet the requirements of novelty based on a technical aspect of the European intellectual property law.

We disagree with this

decision and have appealed the decision.

We continue to believe that the Prosl European Patent is indeed novel and that its validity

should be maintained.

There can be no assurance that we will prevail in this matter.

On January 16, 2015, we filed a complaint against

TauroPharm GmbH and its managing directors in the District Court of Cologne, Germany.

In the complaint, we allege violation of the German

Unfair Competition Act by TauroPharm and that TauroPharm is improperly and unfairly using our proprietary information relating to the

composition and manufacture of Neutrolin, in the manufacture and sale of TauroPharm’s products TauroLockTM, TauroLock-HEP100 and

TauroLock-HEP500.

We sought a cease and desist order against TauroPharm from continuing to manufacture and sell any product containing

taurolidine (the API of Neutrolin) and citric acid in addition to possible other components, damages for any sales in the past and the

removal of all such products from the market.

Hearings in this matter were held in the District Court of Cologne, Germany on November

19, 2015, on November 15, 2016 and on November 20, 2018.

A decision was rendered by the Court on December 11, 2018, dismissing the complaint

in its entirety.

We appealed in January 2019.

An oral hearing was held on September 6, 2019.

In view of new arguments brought forward

in this hearing, the Court issued an evidentiary order on September 27, 2019 ordering an expert opinion.

The expert opinion was not in

In a supplementary expert opinion submitted after we had brought forward arguments against the first expert opinion, the expert

confirmed his view.

In an oral hearing held on June 18, 2021, the Court only heard from the expert, and the Court as well as both parties

asked further questions to the expert around his expert opinion.

At the end of the hearing and internal deliberation among the panel of

judges, the Court indicated that it would dismiss our complaint if we did not withdraw the appeal.

As there were no advantages to further

pursuing the matter in view of the Court’s statements, we withdrew the appeal and the proceedings are therefore now closed.

requested an increase of the value in dispute determined by the Court in order to receive a higher reimbursement of costs (as this is

based on the value in dispute under German law) but the request was rejected in view of arguments brought forward against it by our legal

We will have to reimburse costs in the amount of approximately $41,000 plus interest to TauroPharm.

The decisions by the European and German patent offices may

affect patent rights in other jurisdictions.

The prior art on the basis of which the Prosl

European Patent and the German Utility Model have been

found to be invalid may be used to challenge the validity of issued

United States and/or other foreign patents that are directed to the same or similar subject matter, in a court action or in an administrative

proceeding before the USPTO.

Pending United States and/or foreign patent applications may be denied on that basis of that prior art as

Such patents and patent applications include:

2 unchanged sentences

US 9,339,036;

US 17/176,718;

and EP 14150248.4.

we infringe the rights of third parties, we could be prevented from selling products and forced to pay damages and defend against

If we infringe the rights of third parties we could be prevented

from selling products and forced to pay damages and defend against litigation.

our products, methods, processes and other technologies infringe the proprietary rights of other parties, we could incur substantial

costs and we may have to do one or more of the following:

licenses, which may not be available on commercially reasonable terms, if at all;

an infringing product candidate;

our products or processes to avoid infringement;

using the subject matter claimed in the patents held by others;

litigation or administrative proceedings, which may be costly whether we win or lose,

and which could result in a substantial diversion of our financial and management resources.

Related to Dependence on Third Parties

currently have no internal marketing and sales organization and currently rely and intend to continue to rely on third parties

to market, sell, and distribute Neutrolin outside of the U.S.

We may seek a sales partner in the U.S.

if DefenCath receives FDA

approval or we may undertake marketing and sales of DefenCath in the U.S.

If we are unable to enter into or maintain

agreements with third parties to market and sell DefenCath or any other product after approval or are unable to find a sales partner

or establish our own marketing and sales capabilities, we may not be able to generate significant or any product revenues.

We currently have

no sales, marketing, or distribution infrastructure in the EU and have only started to build necessary functions in the U.S.

business strategy for Neutrolin relies on collaborating with larger firms with experience in marketing and selling medical devices

and pharmaceutical products;

for other products we may also rely on such marketing collaborations or out-licensing of our product

Specifically, for Neutrolin, we have a distributor agreement with each of an Emirati, and a South Korean company for

sales and marketing (upon receipt of approval to market in the U.S., which is required for approval to market in South Korea).

We have a commercial collaboration with Hemotech SAS covering France and certain overseas territories.

Assuming we receive applicable

regulatory approval for other markets, we plan to enter into distribution agreements with one or more third parties for the sale

of Neutrolin in various European, Middle East and other markets.

We will be dependent on the firms and individuals with whom we

contract for the success of sales in the countries in which they operate.

However, there can be no assurance that we will be able

to successfully maintain those relationships or establish and maintain additional marketing, sales, or distribution relationships,

nor can there be assurance that such relationships will be successful, or that we will be successful in gaining market acceptance

for our products.

If these firms or individuals do not perform for whatever reason, our business, prospects and results of operations

may be materially adversely affected.

Finding a new or replacement organization for sales and marketing could be difficult, which

would further harm our business, prospects and results of operations.

To the extent that we enter into any marketing, sales, or

distribution arrangements with third parties, our product revenues will be lower than if we marketed and sold our products directly,

and any revenues we receive will depend upon the efforts of such third parties.

we are unable to establish and maintain such third-party sales and marketing relationships, or choose not to do so, we will have

to establish our own in-house capabilities.

To market any of our products directly, we would need to develop a marketing, sales,

and distribution force that has both technical expertise and the ability to support a distribution capability.

The establishment

of a marketing, sales, and distribution capability would take time and significantly increase our costs, possibly requiring substantial

additional capital.

In addition, there is intense competition for proficient sales and marketing personnel, and we may not be

able to attract individuals who have the qualifications necessary to market, sell, and distribute our products.

There can be no

assurance that we will be able to establish internal marketing, sales, or distribution capabilities.

If we are unable to, or choose

not to establish these capabilities, or if the capabilities we establish are not sufficient to meet our needs, we will be required

to establish collaborative marketing, sales, or distribution relationships with third parties, which we might not be able to do

on acceptable terms or at all.

The failure to successfully develop our own marketing and sales infrastructure would have a negative

adverse effect on our business and results of operations.

we or our collaborators are unable to manufacture our products in sufficient quantities or are unable to obtain regulatory approvals

for a manufacturing facility, we may be unable to meet demand for our products and we may lose potential revenues.

Completion of our

clinical trials and commercialization of DefenCath and any other product candidate require access to, or development of, facilities

to manufacture sufficient supplies.

All of our manufacturing processes currently are, and we expect them to continue to be, outsourced

to third parties.

Specifically, we will rely on one or more manufacturers to supply us and/or our distribution partners with commercial

quantities of DefenCath.

If, for any reason, we become unable to rely on our current sources for the manufacture of DefenCath

or any other product candidates or for active pharmaceutical ingredient (“API”), either for clinical trials or for

commercial quantities, then we would need to identify and contract with additional or replacement third-party manufacturers to

manufacture compounds for pre-clinical, clinical, and commercial purposes.

We may not be successful in identifying such additional

or replacement third-party manufacturers, or in negotiating acceptable terms with any that we do identify.

Such third-party manufacturers

must receive FDA or applicable foreign approval before they can produce clinical material or commercial product, and any that

are identified may not receive such approval or may fail to maintain such approval.

We were recently informed by FDA that the

DefenCath NDA cannot be approved in its present form, because of concerns at the third-party manufacturing facility, which must

be resolved to FDA’s satisfaction before the NDA can be approved.

In addition, we may be in competition with other companies

for access to these manufacturers’ facilities and may be subject to delays in manufacturing if the manufacturers give other

clients higher priority than they give to us.

If we are unable to secure and maintain third-party manufacturing capacity, the

development and sales of our products and our financial performance may be materially adversely affected.

we could begin to commercially manufacture DefenCath or any other product candidate on our own, we must obtain regulatory approval

of the manufacturing facility and process.

The manufacture of drugs for clinical and commercial purposes must comply with cGMP

and applicable non-U.S.

● obtain licenses, which

may not be available on commercially reasonable terms, if at all;

● abandon an infringing

product candidate;

● redesign our products

or processes to avoid infringement;

● stop using the subject

matter claimed in the patents held by others;

● pay damages;

● defend litigation or

administrative proceedings, which may be costly whether we win or lose, and which could result

in a substantial diversion of our financial and management resources.

Risks Related to Dependence on Third Parties

We currently have no internal marketing and sales organization

and currently rely and intend to continue to rely on third parties to market, sell, and distribute Neutrolin outside of the U.S.

seek a sales partner in the U.S.

if DefenCath receives FDA approval or we may undertake marketing and sales of DefenCath in the U.S.

If we are unable to enter into or maintain agreements with third parties to market and sell DefenCath or any other product

after approval or are unable to find a sales partner or establish our own marketing and sales capabilities, we may not be able to generate

significant or any product revenues.

We currently have no sales, marketing, or distribution

infrastructure in the EU and have only started to build necessary functions in the U.S.

Our business strategy for Neutrolin relies on

collaborating with larger firms with experience in marketing and selling medical devices and pharmaceutical products;

for other products

we may also rely on such marketing collaborations or out-licensing of our product candidates.

Specifically, for Neutrolin, we have a

distributor agreement with each of an Emirati, and a South Korean company for sales and marketing (upon receipt of approval to market

in the U.S., which is required for approval to market in South Korea).

We have a commercial collaboration with Hemotech SAS covering

France and certain overseas territories.

Assuming we receive applicable regulatory approval for other markets, we plan to enter into

distribution agreements with one or more third parties for the sale of Neutrolin in various European, Middle East and other markets.

We will be dependent on the firms and individuals with whom we contract for the success of sales in the countries in which they operate.

However, there can be no assurance that we will be able to successfully maintain those relationships or establish and maintain additional

marketing, sales, or distribution relationships, nor can there be assurance that such relationships will be successful, or that we will

be successful in gaining market acceptance for our products.

If these firms or individuals do not perform for whatever reason, our business,

prospects and results of operations may be materially adversely affected.

Finding a new or replacement organization for sales and marketing

could be difficult, which would further harm our business, prospects and results of operations.

To the extent that we enter into any

marketing, sales, or distribution arrangements with third parties, our product revenues will be lower than if we marketed and sold our

products directly, and any revenues we receive will depend upon the efforts of such third parties.

If we are unable to establish and maintain such

third-party sales and marketing relationships, or choose not to do so, we will have to establish our own in-house capabilities.

any of our products directly, we would need to develop a marketing, sales, and distribution force that has both technical expertise and

the ability to support a distribution capability.

The establishment of a marketing, sales, and distribution capability would take time

and significantly increase our costs, possibly requiring substantial additional capital.

In addition, there is intense competition for

proficient sales and marketing personnel, and we may not be able to attract individuals who have the qualifications necessary to market,

sell, and distribute our products.

There can be no assurance that we will be able to establish internal marketing, sales, or distribution

capabilities.

If we are unable to, or choose not to establish these capabilities, or if the capabilities we establish are not sufficient

to meet our needs, we will be required to establish collaborative marketing, sales, or distribution relationships with third parties,

which we might not be able to do on acceptable terms or at all.

The failure to successfully develop our own marketing and sales infrastructure

would have a negative adverse effect on our business and results of operations.

If we or our collaborators are unable to manufacture our

products in sufficient quantities or are unable to obtain regulatory approvals for a manufacturing facility, we may be unable to meet

demand for our products and we may lose potential revenues.

Completion of our clinical trials and commercialization

of DefenCath and any other product candidate require access to, or development of, facilities to manufacture sufficient supplies.

of our manufacturing processes currently are, and we expect them to continue to be, outsourced to third parties.

Specifically, we will

rely on one or more manufacturers to supply us and/or our distribution partners with commercial quantities of DefenCath.

reason, we become unable to rely on our current sources for the manufacture of DefenCath or any other product candidates or for active

pharmaceutical ingredient (“API”), either for clinical trials or for commercial quantities, then we would need to identify

and contract with additional or replacement third-party manufacturers to manufacture compounds for pre-clinical, clinical, and commercial

We may not be successful in identifying such additional or replacement third-party manufacturers, or in negotiating acceptable

terms with any that we do identify.

Such third-party manufacturers must receive FDA or applicable foreign approval before they can produce

clinical material or commercial product, and any that are identified may not receive such approval or may fail to maintain such approval.

We were recently informed by FDA that the DefenCath NDA cannot be approved in its present form, because of concerns at the third-party

manufacturing facility, which must be resolved to FDA’s satisfaction before the NDA can be approved.

In addition, we may be in

competition with other companies for access to these manufacturers’ facilities and may be subject to delays in manufacturing if

the manufacturers give other clients higher priority than they give to us.

If we are unable to secure and maintain third-party manufacturing

capacity, the development and sales of our products and our financial performance may be materially adversely affected.

Before we could begin to commercially manufacture

DefenCath or any other product candidate on our own, we must obtain regulatory approval of the manufacturing facility and process.

manufacture of drugs for clinical and commercial purposes must comply with cGMP and applicable non-U.S.

regulatory requirements.

The cGMP requirements govern quality control and documentation policies and procedures.

cGMP requirements govern quality control and documentation policies and procedures.

Complying with cGMP and non-U.S.

regulatory requirements would require that we expend time, money, and effort in production, recordkeeping,

and quality control to assure that the product meets applicable specifications and other requirements.

We would also have to pass

a pre-approval inspection prior to FDA or non-U.S.

regulatory agency approval.

Failure to pass a pre-approval inspection may significantly

delay regulatory approval of our products.

If we fail to comply with these requirements, we would be subject to possible regulatory

action and may be limited in the jurisdictions in which we are permitted to sell our products.

As a result, our business, financial

condition, and results of operations could be materially adversely affected.

and academic collaborators may take actions that delay, prevent, or undermine the success of our products.

operating and financial strategy for the development, clinical testing, manufacture, and commercialization of our product candidates

is heavily dependent on our entering into collaborations with corporations, academic institutions, licensors, licensees, and other

Our current strategy assumes that we will successfully establish and maintain these collaborations or similar relationships.

However, there can be no assurance that we will be successful establishing or maintaining such collaborations.

Some of our existing

collaborations, such as our licensing agreements, are, and future collaborations may be, terminable at the sole discretion of

the collaborator in certain circumstances.

Replacement collaborators might not be available on attractive terms, or at all.

regulatory requirements

would require that we expend time, money, and effort in production, recordkeeping, and quality control to assure that the product meets

applicable specifications and other requirements.

We would also have to pass a pre-approval inspection prior to FDA or non-U.S.

agency approval.

Failure to pass a pre-approval inspection may significantly delay regulatory approval of our products.

If we fail to

comply with these requirements, we would be subject to possible regulatory action and may be limited in the jurisdictions in which we

are permitted to sell our products.

As a result, our business, financial condition, and results of operations could be materially adversely

Corporate and academic collaborators may take actions that delay,

prevent, or undermine the success of our products.

Our operating and financial strategy for the development,

clinical testing, manufacture, and commercialization of our product candidates is heavily dependent on our entering into collaborations

with corporations, academic institutions, licensors, licensees, and other parties.

Our current strategy assumes that we will successfully

establish and maintain these collaborations or similar relationships.

However, there can be no assurance that we will be successful establishing

or maintaining such collaborations.

Some of our existing collaborations, such as our licensing agreements, are, and future collaborations

may be, terminable at the sole discretion of the collaborator in certain circumstances.

Replacement collaborators might not be available

on attractive terms, or at all.

addition, the activities of any collaborator will not be within our control and may not be within our power to influence.

can be no assurance that any collaborator will perform its obligations to our satisfaction or at all, that we will derive any

revenue or profits from such collaborations, or that any collaborator will not compete with us.

If any collaboration is not pursued,

we may require substantially greater capital to undertake on our own the development and marketing of our product candidates and

may not be able to develop and market such products successfully, if at all.

In addition, a lack of development and marketing

collaborations may lead to significant delays in introducing product candidates into certain markets and/or reduced sales of products

in such markets.

provided by collaborators and others upon which we rely that has not been independently verified could turn out to be false, misleading,

or incomplete.

rely on third-party vendors, scientists, and collaborators to provide us with significant data and other information related to

our projects, clinical trials, and business.

If such third parties provide inaccurate, misleading, or incomplete data, our business,

prospects, and results of operations could be materially adversely affected.

rely on third parties to conduct our clinical trials and pre-clinical studies.

If those parties do not successfully carry out

their contractual duties or meet expected deadlines, our product candidates may not advance in a timely manner or at all.

the course of our pre-clinical testing and clinical trials, we rely on third parties, including laboratories, investigators, clinical

contract research organizations (“CROs”), and manufacturers, to perform critical services for us.

For example, we

rely on third parties to conduct our clinical trials and many of our pre-clinical studies, which are required to be conducted

consistent with regulations on Good Laboratory Practice (“GLP”).

CROs and study sites are responsible for many aspects

of the trials, including finding and enrolling subjects for testing and administering the trials.

Although we rely on these third

parties to conduct our pre-clinical and clinical trials, we are responsible for ensuring that each of our trials is conducted

in accordance with its investigational plan and protocol and that the integrity of the studies and resulting data is protected.

Moreover, the FDA and foreign regulatory authorities require us to comply with regulations and standards, commonly referred to

as Good Clinical Practices (“GCPs”), for conducting, monitoring, recording, and reporting the results of clinical

trials to ensure that the data and results are scientifically credible and accurate, and that the trial subjects are adequately

no assurance that any collaborator will perform its obligations to our satisfaction or at all, that we will derive any revenue or profits

from such collaborations, or that any collaborator will not compete with us.

If any collaboration is not pursued, we may require substantially

greater capital to undertake on our own the development and marketing of our product candidates and may not be able to develop and market

such products successfully, if at all.

In addition, a lack of development and marketing collaborations may lead to significant delays

in introducing product candidates into certain markets and/or reduced sales of products in such markets.

Data provided by collaborators and others upon which we rely

that has not been independently verified could turn out to be false, misleading, or incomplete.

rely on third-party vendors, scientists, and collaborators to provide us with significant data and other information related to our projects,

clinical trials, and business.

If such third parties provide inaccurate, misleading, or incomplete data, our business, prospects, and

results of operations could be materially adversely affected.

We rely on third parties to conduct our clinical trials and

pre-clinical studies.

If those parties do not successfully carry out their contractual duties or meet expected deadlines, our product

candidates may not advance in a timely manner or at all.

In the course of our pre-clinical testing and

clinical trials, we rely on third parties, including laboratories, investigators, clinical contract research organizations (“CROs”),

and manufacturers, to perform critical services for us.

For example, we rely on third parties to conduct our clinical trials and many

of our pre-clinical studies, which are required to be conducted consistent with regulations on Good Laboratory Practice (“GLP”).

CROs and study sites are responsible for many aspects of the trials, including finding and enrolling subjects for testing and administering

Although we rely on these third parties to conduct our pre-clinical and clinical trials, we are responsible for ensuring

that each of our trials is conducted in accordance with its investigational plan and protocol and that the integrity of the studies and

resulting data is protected.

Moreover, the FDA and foreign regulatory authorities require us to comply with regulations and standards,

commonly referred to as Good Clinical Practices (“GCPs”), for conducting, monitoring, recording, and reporting the results

of clinical trials to ensure that the data and results are scientifically credible and accurate, and that the trial subjects are adequately

informed of the potential risks of participating in clinical trials.

Our reliance on third parties does not relieve us of these

responsibilities and requirements.

These third parties may not be available when we need them or, if they are available, may not

comply with all regulatory and contractual requirements or may not otherwise perform their services in a timely or acceptable

manner, and we may need to enter into new arrangements with alternative third parties and our clinical trials may be extended,

delayed or terminated.

These independent third parties may also have relationships with other commercial entities, some of which

may compete with us.

In addition, if such third parties fail to perform their obligations in compliance with our protocols or

the applicable regulatory requirements, our trials may not meet regulatory requirements or may need to be repeated, we may not

receive marketing approvals, or we or such third parties may face regulatory enforcement.

As a result of our dependence on third

parties, we may face delays, failures or cost increases outside of our direct control.

These risks also apply to the development

activities of collaborators, and we do not control their research and development, clinical trial or regulatory activities.

will depend on third party suppliers and contract manufacturers for the manufacturing of our product candidates and have no direct

control over the cost of manufacturing our product candidates.

Increases in the cost of manufacturing our product candidates would

increase our costs of conducting clinical trials and could adversely affect our future profitability.

do not intend to manufacture our product candidates ourselves, and we will rely on third parties for our drug supplies both for

clinical trials and for commercial quantities in the future.

We have taken the strategic decision not to manufacture API for our

product candidates, as these can be more economically supplied by third parties with particular expertise in this area.

identified contract facilities that are registered with the FDA, have a track record of large-scale API manufacture, and have

already invested in capital and equipment.

We have no direct control over the manufacturing of our product candidates, or the

cost thereof.

If the contract manufacturers are unable to produce sufficient quantities of our product candidates, as a result

of a lack of available materials or otherwise, our ability to complete product candidate development and our future profitability

would be adversely affected.

If the cost of manufacturing increases, or if the cost of the materials used increases, these costs

will be passed on to us, making the cost of conducting clinical trials more expensive.

For example, there could be issues securing

the API heparin for our product as a result of the outbreak of African swine fever in China in 2019, which threatened the global

Our reliance on third parties does not relieve us of these responsibilities

and requirements.

These third parties may not be available when we need them or, if they are available, may not comply with all regulatory

and contractual requirements or may not otherwise perform their services in a timely or acceptable manner, and we may need to enter into

new arrangements with alternative third parties and our clinical trials may be extended, delayed or terminated.

These independent third

parties may also have relationships with other commercial entities, some of which may compete with us.

In addition, if such third parties

fail to perform their obligations in compliance with our protocols or the applicable regulatory requirements, our trials may not meet

regulatory requirements or may need to be repeated, we may not receive marketing approvals, or we or such third parties may face regulatory

As a result of our dependence on third parties, we may face delays, failures or cost increases outside of our direct control.

These risks also apply to the development activities of collaborators, and we do not control their research and development, clinical

trial or regulatory activities.

We will depend on third party suppliers and contract manufacturers

for the manufacturing of our product candidates and have no direct control over the cost of manufacturing our product candidates.

in the cost of manufacturing our product candidates would increase our costs of conducting clinical trials and could adversely affect

our future profitability.

We do not intend to manufacture our product candidates

ourselves, and we will rely on third parties for our drug supplies both for clinical trials and for commercial quantities in the future.

We have taken the strategic decision not to manufacture API for our product candidates, as these can be more economically supplied by

third parties with particular expertise in this area.

We have identified contract facilities that are registered with the FDA, have a

track record of large-scale API manufacture, and have already invested in capital and equipment.

We have no direct control over the manufacturing

of our product candidates, or the cost thereof.

If the contract manufacturers are unable to produce sufficient quantities of our product

candidates, as a result of a lack of available materials or otherwise, our ability to complete product candidate development and our

future profitability would be adversely affected.

If the cost of manufacturing increases, or if the cost of the materials used increases,

these costs will be passed on to us, making the cost of conducting clinical trials more expensive.

For example, there could be issues

securing the API heparin for our product as a result of the outbreak of African swine fever in China in 2019, which threatened the global

heparin supply.

The United States is largely dependent on China for its heparin, because almost half of the global pig supply,

the main animal source for heparin, is in China.

Increases in manufacturing costs could adversely affect our future profitability

if we are unable to pass all of the increased costs along to our customers.

we, along with our contract manufacturers, are required to comply with FDA requirements for cGMPs, related to product testing,

quality assurance, manufacturing and documentation.

Our contract manufacturers may not be able to comply with the applicable FDA

regulatory requirements, which could result in delays to our product development programs, could result in adverse regulatory

actions against them or us, and could prevent us from ultimately receiving product marketing approval.

They also generally must

pass an FDA preapproval inspection for conformity with cGMPs before we can obtain approval to manufacture our product candidates

and will be subject to ongoing, periodic, unannounced inspection by the FDA and corresponding state agencies to ensure strict

compliance with cGMP, and other applicable government regulations and corresponding foreign standards.

If we and our contract

manufacturers fail to achieve and maintain high manufacturing standards in compliance with cGMP, we may experience manufacturing

errors resulting in defective products that could be harmful to patients, product recalls or withdrawals, delays or interruptions

of production or failures in product testing or delivery, delay or prevention of filing or approval of marketing applications

for our products, cost overruns or other problems that could seriously harm our business.

The United States is largely dependent on China for its heparin, because almost half of the global pig supply, the main

animal source for heparin, is in China.

Increases in manufacturing costs could adversely affect our future profitability if we are unable

to pass all of the increased costs along to our customers.

Further, we, along with our contract manufacturers,

are required to comply with FDA requirements for cGMPs, related to product testing, quality assurance, manufacturing and documentation.

Our contract manufacturers may not be able to comply with the applicable FDA regulatory requirements, which could result in delays to

our product development programs, could result in adverse regulatory actions against them or us, and could prevent us from ultimately

receiving product marketing approval.

They also generally must pass an FDA preapproval inspection for conformity with cGMPs before we

can obtain approval to manufacture our product candidates and will be subject to ongoing, periodic, unannounced inspection by the FDA

and corresponding state agencies to ensure strict compliance with cGMP, and other applicable government regulations and corresponding

foreign standards.

If we and our contract manufacturers fail to achieve and maintain high manufacturing standards in compliance with

cGMP, we may experience manufacturing errors resulting in defective products that could be harmful to patients, product recalls or withdrawals,

delays or interruptions of production or failures in product testing or delivery, delay or prevention of filing or approval of marketing

applications for our products, cost overruns or other problems that could seriously harm our business.

Not complying with FDA requirements

could result in a product recall or prevent commercialization of our product candidates and delay our business development activities.

In addition, such failure could be the basis for the FDA to issue a warning or untitled letter or take other regulatory or legal

enforcement action, including recall or seizure, total or partial suspension of production, suspension of ongoing clinical trials,

refusal to approve pending applications or supplemental applications, and potentially civil and/or criminal penalties depending

on the matter.

Related to our Common Stock

will need additional financing to fund our activities in the future, which likely will dilute our stockholders.

commercial operations have not generated sufficient revenues to enable profitability.

As of December 31, 2020, we had an

accumulated deficit of $217.4 million, and incurred net losses of $22.0 million for the year then ended.

Based on the current

development plans for DefenCath/Neutrolin in both the U.S.

and foreign markets (including the preparation of an NDA for

DefenCath in hemodialysis catheters) and our other operating requirements, management believes that the existing cash at

December 31, 2020, will be sufficient to fund operations at least into the second half of 2022, after taking into

consideration the $41.5 million of net proceeds received in January and February 2021 from the at-the-market program.

Further, we will need additional funding for DefenCath’s commercial launch.

We anticipate that we will incur operating

losses for the foreseeable future.

In addition, such failure could be the basis for the FDA to issue a warning or untitled letter or take other regulatory or legal enforcement

action, including recall or seizure, total or partial suspension of production, suspension of ongoing clinical trials, refusal to approve

pending applications or supplemental applications, and potentially civil and/or criminal penalties depending on the matter.

Risks Related to our Common Stock

We will need additional financing to fund our activities in

the future, which likely will dilute our stockholders.

To date, our commercial operations have not generated

sufficient revenues to enable profitability.

As of December 31, 2021, we had an accumulated deficit of $245.7 million, and incurred net

losses of $28.2 million for the year then ended.

Based on the current development plans for DefenCath/Neutrolin in both the U.S.

markets (including the resubmission of an NDA for DefenCath in hemodialysis catheters) and our other operating requirements, management

believes that the existing cash at December 31, 2021, will be sufficient to fund operations at least through the first half of 2023, after

taking into consideration the costs for resubmission of the NDA and initial preparations for the commercial launch for DefenCath.

we will need additional funding for DefenCath’s commercial launch.

We anticipate that we will incur operating losses for the foreseeable

Additionally, we will require substantial funds in the future to support our operations.

Accordingly, we will need to obtain additional financing, including through issuances of equity securities.

Accordingly, we will need to obtain additional

financing, including through issuances of equity securities.

the extent we raise additional capital by issuing equity securities, our stockholders may experience substantial dilution.

may, as we have in the past, sell common stock, convertible securities or other equity securities in one or more transactions

at prices and in a manner we determine from time to time.

If we sell common stock, convertible securities or other equity securities

in more than one transaction, investors may be further diluted by subsequent sales.

Such sales may also result in material dilution

to our existing stockholders, and new investors could gain rights superior to existing stockholders.

executive officers and directors may sell shares of their stock, and these sales could adversely affect our stock price.

of our common stock by our executive officers and directors, or the perception that such sales may occur, could adversely affect

the market price of our common stock.

Our executive officers and directors may sell stock in the future, either as part, or outside,

of trading plans under Rule 10b5-1 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”).

common stock price has fluctuated considerably and is likely to remain volatile, in part due to the limited market for our common

stock and you could lose all or a part of your investment.

the period from the completion of our initial public offering (“IPO”), on March 30, 2010 through December 31, 2020,

the high and low sales prices for our common stock were $52.00 and $0.75, respectively.

There is a limited public market for our

common stock and we cannot provide assurances that an active trading market will develop or continue.

As a result of low trading

volume in our common stock, the purchase or sale of a relatively small number of shares could result in significant share price

fluctuations.

Additionally,

the market price of our common stock may continue to fluctuate significantly in response to a number of factors, some of which

are beyond our control, including the following:

receipt of or failure to obtain additional regulatory approvals for DefenCath, including

FDA approval in the U.S.;

acceptance of Neutrolin in those markets in which it is approved for sale;

need for additional capital;

of clinical trials of our product candidates, including any other Phase 3 trial for DefenCath

in the U.S., if required, or those of our competitors;

entry into or the loss of a significant collaboration, or expiration or termination of

or legal developments in the United States and other countries, including changes in

the healthcare payment systems;

in financial estimates or investment recommendations by securities analysts relating

to our common stock;

sales or anticipated sales of our securities by us or our stockholders;

● announcements

by our competitors of significant developments, technological innovations, strategic

partnerships, joint ventures or capital commitments;

in key personnel;

in our financial results or those of companies that are perceived to be similar to us;

or anticipated variations in operating results;

conditions in the pharmaceutical and medical device sectors and issuance of new or changed

securities analysts’ reports or recommendations;

● instability

in the stock market as a result of current or future domestic and global events;

of any market for our securities;

or actual delisting of our common stock from a national stock exchange;

economic, industry and market conditions;

● developments

or disputes concerning patents or other proprietary rights;

other factors described in this “Risk Factors” section.

addition, the stock markets in general, and the stock of pharmaceutical and medical device companies in particular, have experienced

extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these

In addition, changes in economic conditions in the U.S., the European Union or globally, particularly in the context

of current global events, could impact upon our ability to grow profitably.

Adverse economic changes are outside our control and

may result in material adverse impacts on our business or our results of operations.

Broad market and industry factors may negatively

affect the market price of our common stock, regardless of our actual operating performance.

In the past, following periods of

volatility in the market price of a company’s securities, securities class-action litigation has often been instituted against

that company.

Such litigation, if instituted against us, could cause us to incur substantial costs and divert management’s

attention and resources.

these reasons and others, an investment in our securities is risky and you should invest only if you can withstand wide fluctuations

in and a significant or complete loss of the value of your investment.

significant number of additional shares of our common stock may be issued at a later date, and their sale could depress the market

price of our common stock.

of December 31, 2020, we had outstanding the following securities that are convertible into or exercisable for shares of our common

to purchase an aggregate of 15,334 shares of our common stock issued to our officers,

directors, employees and non-employee consultants under our 2006 Stock Plan, with a weighted

average exercise price of $6.18 per share;

to purchase an aggregate of 1,325,369 shares of our common stock issued to our officers,

directors and non-employee consultants under our 2013 Stock Plan, with a weighted average

exercise price of $8.99 per share;

to purchase an aggregate of 1,106,984 shares of our common stock issued to our officers,

directors and non-employee consultants under our 2019 Stock Plan, with a weighted average

exercise price of $5.11 per share;

shares of Series C-3 Preferred Stock, which are convertible into 104,000 shares of common

shares of Series E Preferred Stock, which are convertible into 391,953 shares of common

shares of Series G Preferred Stock, which are convertible into 5,560,137 shares of common

to purchase an aggregate of 183,148 shares of common stock with a weighted average exercise

price of $4.96 per share.

Additionally, there

are 2,490,903 shares of common stock available for grants under the 2019 Stock Plan (adopted on November 26, 2019).

possibility of the issuance of these shares, as well as the actual sale of such shares, could substantially reduce the market

price for our common stock and impede our ability to obtain future financing.

in our corporate charter documents and under Delaware law could make an acquisition of us, which may be beneficial to our stockholders,

more difficult.

in our Amended and Restated Certificate of Incorporation, as amended, and our Amended and Restated Bylaws, as well as provisions

of the General Corporation Law of the State of Delaware, or DGCL, may discourage, delay or prevent a merger, acquisition or other

change in control of our company, even if such a change in control would be beneficial to our stockholders.

These provisions include

we have in the past, sell common stock, convertible securities or other equity securities in one or more transactions at prices and in

a manner we determine from time to time.

If we sell common stock, convertible securities or other equity securities in more than one

transaction, investors may be further diluted by subsequent sales.

Such sales may also result in material dilution to our existing stockholders,

and new investors could gain rights superior to existing stockholders.

Our executive officers and directors may sell shares of their

stock, and these sales could adversely affect our stock price.

Sales of our common stock by our executive officers

and directors, or the perception that such sales may occur, could adversely affect the market price of our common stock.

Our executive

officers and directors may sell stock in the future, either as part, or outside, of trading plans under Rule 10b5-1 under the Securities

Exchange Act of 1934, as amended (the “Exchange Act”).

Our common stock price has fluctuated considerably and is likely

to remain volatile, in part due to the limited market for our common stock and you could lose all or a part of your investment.

the period from the completion of our initial public offering (“IPO”), on March 30, 2010 through December 31, 2021, the high

and low sales prices for our common stock were $52.00 and $0.75, respectively.

There is a limited public market for our common stock

and we cannot provide assurances that an active trading market will develop or continue.

As a result of low trading volume in our common

stock, the purchase or sale of a relatively small number of shares could result in significant share price fluctuations.

Additionally, the market price of our

common stock may continue to fluctuate significantly in response to a number of factors, some of which are beyond our control, including

the following:

● authorizing

the issuance of “blank check” preferred stock, the terms of which may be

established and shares of which may be issued without stockholder approval;

● prohibiting

our stockholders from fixing the number of our directors;

● establishing

advance notice requirements for stockholder proposals that can be acted on at stockholder

meetings and nominations to our Board of Directors.

provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it

more difficult for stockholders to replace members of our board of directors, which is responsible for appointing the members

of our management.

In addition, we are subject to Section 203 of the DGCL, which generally prohibits a Delaware corporation from

engaging in any of a broad range of business combinations with an interested stockholder for a period of three years following

the date on which the stockholder became an interested stockholder, unless such transactions are approved by the board of directors.

This provision could have the effect of discouraging, delaying or preventing someone from acquiring us or merging with us, whether

or not it is desired by, or beneficial to, our stockholders.

Any provision of our Amended and Restated Certificate of Incorporation,

as amended, or Amended and Restated Bylaws or Delaware law that has the effect of delaying or deterring a change in control could

limit the opportunity for our stockholders to receive a premium for their shares of our common stock and could also affect the

price that some investors are willing to pay for our common stock.

we fail to comply with the continued listing standards of the Nasdaq Global Market, it may result in a delisting of our common

stock from the exchange.

Our common stock

is currently listed for trading on the Nasdaq Global Market under the symbol “CRMD”, and the continued listing of

our common stock on the Nasdaq Global Market is subject to our compliance with a number of listing standards.

If we fail to satisfy

the continued listing requirements of The Nasdaq Capital Market such as the corporate governance requirements, the stockholder’s

equity requirement or the minimum closing bid price requirement, The Nasdaq Capital Market may take steps to de-list our common

Such a de-listing or even notification of failure to comply with such requirements would likely have a negative effect

on the price of our common stock and would impair your ability to sell or purchase our common stock when you wish to do so.

addition, the delisting of our common stock could materially adversely impact our ability to raise capital on acceptable terms

Delisting from Nasdaq could also have other negative results, including the potential loss of confidence by our current

or prospective third-party providers and collaboration partners, the loss of institutional investor interest, and fewer licensing

and partnering.

In the event of a de-listing, we would take actions to restore our compliance with The Nasdaq Capital Market’s

listing requirements, but we can provide no assurance that any such action taken by us would allow our common stock to become

listed again, stabilize the market price or improve the liquidity of our common stock.

our common stock were no longer listed on the Nasdaq Global Market, investors might only be able to trade on one of the over-the-counter

markets, including the OTC Bulletin Board ®

or in the Pink Sheets ®

(a quotation medium operated

by Pink Sheets LLC).

This would impair the liquidity of our common stock not only in the number of shares that could be bought

and sold at a given price, which might be depressed by the relative illiquidity, but also through delays in the timing of transactions

and reduction in media coverage.

rules and regulations relating to public companies may be costly and impact our ability to attract and retain directors and executive

and regulations affecting public companies, including rules adopted by the Securities and Exchange Commission (“SEC”)

and by the Nasdaq Global Market, may result in increased costs to us.

These laws, rules and regulations could make it more difficult

or costly for us to obtain certain types of insurance, including director and officer liability insurance, and we may be forced

to accept reduced policy limits and coverage or incur substantially higher costs to obtain the same or similar coverage.

of these events could also make it more difficult for us to attract and retain qualified persons to serve on our board of directors,

on our board committees or as executive officers.

We cannot estimate accurately the amount or timing of additional costs we may

incur to respond to these laws, rules and regulations.

internal control over financial reporting and our disclosure controls and procedures may not prevent all possible errors that

management is responsible for establishing and maintaining adequate internal control over financial reporting to provide reasonable

assurance regarding the reliability of our financial reporting and the preparation of financial statements for external purposes

in accordance with accounting principles generally accepted in the United States of America (“U.S.

that we have adequate internal financial and accounting controls and procedures in place to produce accurate financial statements

on a timely basis is a costly and time-consuming effort that needs to be re-evaluated frequently.

Failure on our part to have

effective internal financial and accounting controls would cause our financial reporting to be unreliable, could have a material

adverse effect on our business, operating results, and financial condition, and could cause the trading price of our common stock

to fall dramatically.

control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control

system’s objectives will be satisfied.

Internal control over financial reporting and disclosure controls and procedures

are designed to give a reasonable assurance that they are effective to achieve their objectives.

We cannot provide absolute assurance

that all of our possible future control issues will be detected.

These inherent limitations include the possibility that judgments

in our decision making can be faulty, and that isolated breakdowns can occur because of simple human error or mistake.

of our system of controls is based in part upon assumptions about the likelihood of future events, and there can be no assurance

that any design will succeed absolutely in achieving our stated goals under all potential future or unforeseeable conditions.

Because of the inherent limitations in a cost-effective control system, misstatements due to error could occur and not be detected.

This and any future failures could cause investors to lose confidence in our reported financial information, which could have

a negative impact on our financial condition and stock price.

future periods, if the process required by Section 404 of the Sarbanes-Oxley Act reveals any material weaknesses or significant

deficiencies, the correction of any such material weaknesses or significant deficiencies could require remedial measures which

could be costly and time-consuming.

In addition, in such a case, we may be unable to produce accurate financial statements on

a timely basis.

Any associated accounting restatement could create a significant strain on our internal resources and cause delays

in our release of quarterly or annual financial results and the filing of related reports, increase our costs and cause management

Any of the foregoing could cause investors to lose confidence in the reliability of our financial statements, which

could cause the market price of our common stock to decline and make it more difficult for us to finance our operations and growth.

breaches and other disruptions could compromise our information and expose us to liability, which would cause our business and

reputation to suffer.

the ordinary course of our business, we collect and store sensitive data, including intellectual property, our proprietary business

information and that of our suppliers, as well as personally identifiable information of clinical trial participants and employees.

Similarly, our third-party providers possess certain of our sensitive protected health data.

The secure maintenance of this information

is critical to our operations and business strategy.

Despite our security measures, our information technology and infrastructure

may be vulnerable to attacks by hackers or breached due to employee error, malfeasance or other disruptions.

Attacks of this nature

are increasing in their frequency, levels of persistence, sophistication and intensity, and are being conducted by sophisticated

and organized groups and individuals with a wide range of motives and expertise.

Although we develop and maintain systems and

controls designed to prevent these events from occurring, and we have a process to identify and mitigate threats, the development

and maintenance of these systems, controls and processes is costly and requires ongoing monitoring and updating as technologies

change and efforts to overcome security measures become more sophisticated, and such systems, controls and processes may not be

successful in preventing a breach.

Any such breach could compromise our networks and the information stored there could be accessed,

publicly disclosed, lost or stolen.

We could be required to expend significant amounts of money and other resources to repair

or replace information systems or networks.

In addition, our liability insurance may not be sufficient in type or amount to cover

us against claims related to security breaches, cyberattacks and other related breaches.

legislative and regulatory landscape for privacy and data protection continues to evolve, and there has been an increasing amount

of focus on privacy and data protection issues with the potential to affect our business, including compliance with the Health

Insurance Portability and Accountability Act of 1996 and recently enacted laws in a majority of states requiring security breach

notification.

The collection and use of personal health data of individuals in the European Union is also governed by strict data

protection laws.

In addition to existing laws, since May 25, 2018, the General Data Protection Regulation (“GDPR”)

has imposed new obligations with respect to European Union data and substantial fines for breaches of the data protection rules.

It will increase our responsibility and potential liability in relation to personal data that we process, and we will be required

to put in place additional mechanisms ensuring compliance with the new European Union data protection rules.

There is significant

uncertainty related to the manner in which data protection authorities will seek to enforce compliance with GDPR.

it is not clear if the authorities will conduct random audits of companies doing business in the European Union, or if the authorities

will wait for complaints to be filed by individuals who claim their rights have been violated.

Enforcement uncertainty and the

costs associated with ensuring GDPR compliance may be onerous and adversely affect our business, operating results, prospects

● the receipt of or failure

to obtain additional regulatory approvals for DefenCath, including FDA approval in the U.S.;

● market acceptance of

Neutrolin in those markets in which it is approved for sale;

● our need for additional

● results of clinical

trials of our product candidates, including any other Phase 3 trial for DefenCath in the

U.S., if required, or those of our competitors;

● our entry into or the

loss of a significant collaboration, or expiration or termination of licenses;

● regulatory or legal

developments in the United States and other countries, including changes in the healthcare

payment systems;

● changes in financial

estimates or investment recommendations by securities analysts relating to our common stock;

● future sales or anticipated

sales of our securities by us or our stockholders;

● announcements by our

competitors of significant developments, technological innovations, strategic partnerships,

joint ventures or capital commitments;

● changes in key personnel;

● variations in our financial

results or those of companies that are perceived to be similar to us;

● actual or anticipated

variations in operating results;

● market conditions in

the pharmaceutical and medical device sectors and issuance of new or changed securities analysts’

reports or recommendations;

● instability in the

stock market as a result of current or future domestic and global events;

● liquidity of any market

for our securities;

● threatened or actual

delisting of our common stock from a national stock exchange;

● general economic, industry

and market conditions;

● developments or disputes

concerning patents or other proprietary rights;

● any other factors described in this “Risk Factors”

In addition, the stock markets in general, and

the stock of pharmaceutical and medical device companies in particular, have experienced extreme price and volume fluctuations that have

often been unrelated or disproportionate to the operating performance of these companies.

In addition, changes in economic conditions

in the U.S., the European Union or globally, particularly in the context of current global events, could impact upon our ability to grow

Adverse economic changes are outside our control and may result in material adverse impacts on our business or our results

of operations.

Broad market and industry factors may negatively affect the market price of our common stock, regardless of our actual

operating performance.

In the past, following periods of volatility in the market price of a company’s securities, securities class-action

litigation has often been instituted against that company.

Such litigation, if instituted against us, could cause us to incur substantial

costs and divert management’s attention and resources.

For these reasons and others, an investment

in our securities is risky and you should invest only if you can withstand wide fluctuations in and a significant or complete loss of

the value of your investment.

A significant number of additional shares of our common stock

may be issued at a later date, and their sale could depress the market price of our common stock.

As of December 31, 2021, we had outstanding

the following securities that are convertible into or exercisable for shares of our common stock:

● options to purchase

an aggregate of 1,034,984 shares of our common stock issued to our officers, directors and

non-employee consultants under our 2013 Stock Plan, with a weighted average exercise price

of $9.47 per share;

● options to purchase

an aggregate of 2,323,147 shares of our common stock issued to our officers, directors and

non-employee consultants under our 2019 Stock Plan, with a weighted average exercise price

of $6.67 per share;

● 2,000 shares of Series

C-3 Preferred Stock, which are convertible into 4,000 shares of common stock;

● 89,623 shares of Series

E Preferred Stock, which are convertible into 391,953 shares of common stock;

● 89,999 shares of Series

G Preferred Stock, which are convertible into 5,004,069 shares of common stock;

warrants to purchase an aggregate of 56,455 shares of common stock with a weighted average exercise price of $5.25 per share;

48,909,shares of common stock issuable for payment of deferred board compensation.

Additionally, there are 1,547,725 shares of common

stock available for grants under the 2019 Stock Plan (adopted on November 26, 2019).

The possibility of the issuance of these

shares, as well as the actual sale of such shares, could substantially reduce the market price for our common stock and impede our ability

to obtain future financing.

Provisions in our corporate charter documents and under Delaware

law could make an acquisition of us, which may be beneficial to our stockholders, more difficult.

Provisions in our Amended and Restated Certificate of Incorporation,

as amended, and our Amended and Restated Bylaws, as well as provisions of the General Corporation Law of the State of Delaware, or DGCL,

may discourage, delay or prevent a merger, acquisition or other change in control of our Company, even if such a change in control would

be beneficial to our stockholders.

These provisions include the following:

● authorizing the issuance

of “blank check” preferred stock, the terms of which may be established and shares

of which may be issued without stockholder approval;

● prohibiting our stockholders

from fixing the number of our directors;

● establishing advance

notice requirements for stockholder proposals that can be acted on at stockholder meetings

and nominations to our Board of Directors.

These provisions may frustrate or prevent any

attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members

of our board of directors, which is responsible for appointing the members of our management.

In addition, we are subject to Section

203 of the DGCL, which generally prohibits a Delaware corporation from engaging in any of a broad range of business combinations with

an interested stockholder for a period of three years following the date on which the stockholder became an interested stockholder, unless

such transactions are approved by the board of directors.

This provision could have the effect of discouraging, delaying or preventing

someone from acquiring us or merging with us, whether or not it is desired by, or beneficial to, our stockholders.

Any provision of our

Amended and Restated Certificate of Incorporation, as amended, or Amended and Restated Bylaws or Delaware law that has the effect of

delaying or deterring a change in control could limit the opportunity for our stockholders to receive a premium for their shares of our

common stock and could also affect the price that some investors are willing to pay for our common stock.

If we fail to comply with the continued listing standards of

the Nasdaq Global Market, it may result in a delisting of our common stock from the exchange.

Our common stock is currently listed for trading

on the Nasdaq Global Market under the symbol “CRMD”, and the continued listing of our common stock on the Nasdaq Global Market

is subject to our compliance with a number of listing standards.

If we fail to satisfy the continued listing requirements of The Nasdaq

Capital Market such as the corporate governance requirements, the stockholder’s equity requirement or the minimum closing bid price

requirement, The Nasdaq Capital Market may take steps to de-list our common stock.

Such a de-listing or even notification of failure

to comply with such requirements would likely have a negative effect on the price of our common stock and would impair your ability to

sell or purchase our common stock when you wish to do so.

In addition, the delisting of our common stock could materially adversely impact

our ability to raise capital on acceptable terms or at all.

Delisting from Nasdaq could also have other negative results, including the

potential loss of confidence by our current or prospective third-party providers and collaboration partners, the loss of institutional

investor interest, and fewer licensing and partnering.

In the event of a de-listing, we would take actions to restore our compliance

with The Nasdaq Capital Market’s listing requirements, but we can provide no assurance that any such action taken by us would allow

our common stock to become listed again, stabilize the market price or improve the liquidity of our common stock.

If our common stock were no longer listed on the

Nasdaq Global Market, investors might only be able to trade on one of the over-the-counter markets, including the OTC Bulletin Board

® or in the Pink Sheets ® (a quotation medium operated by Pink Sheets LLC).

This would impair the liquidity

of our common stock not only in the number of shares that could be bought and sold at a given price, which might be depressed by the

relative illiquidity, but also through delays in the timing of transactions and reduction in media coverage.

Laws, rules and regulations relating to public companies may

be costly and impact our ability to attract and retain directors and executive officers.

Laws and regulations affecting public companies,

including rules adopted by the Securities and Exchange Commission (“SEC”) and by the Nasdaq Global Market, may result in

increased costs to us.

These laws, rules and regulations could make it more difficult or costly for us to obtain certain types of insurance,

including director and officer liability insurance, and we may be forced to accept reduced policy limits and coverage or incur substantially

higher costs to obtain the same or similar coverage.

The impact of these events could also make it more difficult for us to attract and

retain qualified persons to serve on our board of directors, on our board committees or as executive officers.

We cannot estimate accurately

the amount or timing of additional costs we may incur to respond to these laws, rules and regulations.

Our internal control over financial reporting and our disclosure

controls and procedures may not prevent all possible errors that could occur.

Our management is responsible for establishing

and maintaining adequate internal control over financial reporting to provide reasonable assurance regarding the reliability of our financial

reporting and the preparation of financial statements for external purposes in accordance with accounting principles generally accepted

in the United States of America (“U.S.

Ensuring that we have adequate internal financial and accounting controls

and procedures in place to produce accurate financial statements on a timely basis is a costly and time-consuming effort that needs to

be re-evaluated frequently.

Failure on our part to have effective internal financial and accounting controls would cause our financial

reporting to be unreliable, could have a material adverse effect on our business, operating results, and financial condition, and could

cause the trading price of our common stock to fall dramatically.

A control system, no matter how well designed

and operated, can provide only reasonable, not absolute, assurance that the control system’s objectives will be satisfied.

control over financial reporting and disclosure controls and procedures are designed to give a reasonable assurance that they are effective

to achieve their objectives.

We cannot provide absolute assurance that all of our possible future control issues will be detected.

inherent limitations include the possibility that judgments in our decision making can be faulty, and that isolated breakdowns can occur

because of simple human error or mistake.

The design of our system of controls is based in part upon assumptions about the likelihood

of future events, and there can be no assurance that any design will succeed absolutely in achieving our stated goals under all potential

future or unforeseeable conditions.

Because of the inherent limitations in a cost-effective control system, misstatements due to error

could occur and not be detected.

This and any future failures could cause investors to lose confidence in our reported financial information,

which could have a negative impact on our financial condition and stock price.

In future periods, if the process required by

Section 404 of the Sarbanes-Oxley Act reveals any material weaknesses or significant deficiencies, the correction of any such material

weaknesses or significant deficiencies could require remedial measures which could be costly and time-consuming.

In addition, in such

a case, we may be unable to produce accurate financial statements on a timely basis.

Any associated accounting restatement could create

a significant strain on our internal resources and cause delays in our release of quarterly or annual financial results and the filing

of related reports, increase our costs and cause management distraction.

Any of the foregoing could cause investors to lose confidence

in the reliability of our financial statements, which could cause the market price of our common stock to decline and make it more difficult

for us to finance our operations and growth.

Security breaches and other disruptions could compromise our

information and expose us to liability, which would cause our business and reputation to suffer.

In the ordinary course of our business, we collect

and store sensitive data, including intellectual property, our proprietary business information and that of our suppliers, as well as

personally identifiable information of clinical trial participants and employees.

Similarly, our third-party providers possess certain

of our sensitive protected health data.

The secure maintenance of this information is critical to our operations and business strategy.

Despite our security measures, our information technology and infrastructure may be vulnerable to attacks by hackers or breached due

to employee error, malfeasance or other disruptions.

Attacks of this nature are increasing in their frequency, levels of persistence,

sophistication and intensity, and are being conducted by sophisticated and organized groups and individuals with a wide range of motives

and expertise.

Although we develop and maintain systems and controls designed to prevent these events from occurring, and we have a process

to identify and mitigate threats, the development and maintenance of these systems, controls and processes is costly and requires ongoing

monitoring and updating as technologies change and efforts to overcome security measures become more sophisticated, and such systems,

controls and processes may not be successful in preventing a breach.

Any such breach could compromise our networks and the information

stored there could be accessed, publicly disclosed, lost or stolen.

We could be required to expend significant amounts of money and other

resources to repair or replace information systems or networks.

In addition, our liability insurance may not be sufficient in type or

amount to cover us against claims related to security breaches, cyberattacks and other related breaches.

The legislative and regulatory landscape for privacy

and data protection continues to evolve, and there has been an increasing amount of focus on privacy and data protection issues with

the potential to affect our business, including compliance with the Health Insurance Portability and Accountability Act of 1996 and recently

enacted laws in a majority of states requiring security breach notification.

The collection and use of personal health data of individuals

in the European Union is also governed by strict data protection laws.

In addition to existing laws, since May 25, 2018, the General

Data Protection Regulation (“GDPR”) has imposed new obligations with respect to European Union data and substantial fines

for breaches of the data protection rules.

It will increase our responsibility and potential liability in relation to personal data that

we process, and we will be required to put in place additional mechanisms ensuring compliance with the new European Union data protection

There is significant uncertainty related to the manner in which data protection authorities will seek to enforce compliance with

For example, it is not clear if the authorities will conduct random audits of companies doing business in the European Union, or

if the authorities will wait for complaints to be filed by individuals who claim their rights have been violated.

Enforcement uncertainty

and the costs associated with ensuring GDPR compliance may be onerous and adversely affect our business, operating results, prospects

and financial condition.

Additionally,

California recently enacted legislation that has been dubbed the first “GDPR-like” law in the United States.

as the California Consumer Privacy Act (“CCPA”), it creates new individual privacy rights for consumers (as that word

is broadly defined in the law) and places increased privacy and security obligations on entities handling personal data of consumers

or households.

The CCPA, which went into effect on January 1, 2020, requires covered companies to provide new disclosures to California

consumers, provide such consumers new ways to opt-out of certain sales of personal information, and allow for a new cause of action

for data breaches.

The CCPA may significantly impact our business activities and require substantial compliance costs that adversely

affect business, operating results, prospects and financial condition.

any access, disclosure or other loss of information, including our data being breached at our partners or third-party providers,

could result in legal claims or proceedings and liability under laws that protect the privacy of personal information, disrupt

our operations and damage our reputation, which could adversely affect our business.

do not intend to pay dividends on our common stock so any returns on our common stock will be limited to the value of our common

have never declared dividends on our common stock, and currently do not plan to declare dividends on shares of our common stock

in the foreseeable future.

Pursuant to the terms of our Series C-3, E and G Convertible Preferred Stock, we may not declare or

pay any dividends or make any distributions on any of our shares or other equity securities as long as any of those preferred

shares remain outstanding.

We currently expect to retain future earnings, if any, for use in the operation and expansion of our

The payment of cash dividends in the future, if any, will be at the discretion of our Board of Directors and will depend

upon such factors as earnings levels, capital requirements, our overall financial condition and any other factors deemed relevant

by our Board of Directors.

Any return to holders of our common stock will be limited to the value of their common stock.

Staff Comments

Additionally, California recently enacted legislation

that has been dubbed the first “GDPR-like” law in the United States.

Known as the California Consumer Privacy Act (“CCPA”),

it creates new individual privacy rights for consumers (as that word is broadly defined in the law) and places increased privacy and

security obligations on entities handling personal data of consumers or households.

The CCPA, which went into effect on January 1, 2020,

requires covered companies to provide new disclosures to California consumers, provide such consumers new ways to opt-out of certain

sales of personal information, and allow for a new cause of action for data breaches.

The CCPA may significantly impact our business

activities and require substantial compliance costs that adversely affect business, operating results, prospects and financial condition.

Thus, any access, disclosure or other loss of

information, including our data being breached at our partners or third-party providers, could result in legal claims or proceedings

and liability under laws that protect the privacy of personal information, disrupt our operations and damage our reputation, which could

adversely affect our business.

We do not intend to pay dividends on our common stock so any

returns on our common stock will be limited to the value of our common stock.

We have never declared dividends on our common

stock, and currently do not plan to declare dividends on shares of our common stock in the foreseeable future.

Pursuant to the terms

of our Series C-3, E and G Convertible Preferred Stock, we may not declare or pay any dividends or make any distributions on any of our

shares or other equity securities as long as any of those preferred shares remain outstanding.

We currently expect to retain future earnings,

if any, for use in the operation and expansion of our business.

The payment of cash dividends in the future, if any, will be at the discretion

of our Board of Directors and will depend upon such factors as earnings levels, capital requirements, our overall financial condition

and any other factors deemed relevant by our Board of Directors.

Any return to holders of our common stock will be limited to the value

of their common stock.

Unresolved Staff Comments

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.

What changed 10-K

Item 1A. Risk Factors